105 results on '"COST analysis"'
Search Results
2. A Review of Two Heparin Prophylaxes for Trauma.
- Author
-
Yu, Hyunmin (David)
- Subjects
HEMORRHAGE complications ,HEPARIN ,THROMBOEMBOLISM prevention ,VENOUS thrombosis risk factors ,INJURY complications ,ENOXAPARIN ,CINAHL database ,MEDICAL information storage & retrieval systems ,MEDICAL care costs ,MEDLINE ,ONLINE information services ,PULMONARY embolism ,THROMBOEMBOLISM ,VEINS ,SYSTEMATIC reviews ,COST analysis ,TREATMENT effectiveness ,DISEASE risk factors ,THERAPEUTICS - Abstract
Venous thromboembolism (VTE) prophylaxis has a significant impact on mortality and morbidity in trauma patients. This article reviews 9 published studies that investigate and compare low-dose unfractionated heparin (LDUH) with low-molecular-weight heparin (LMWH) for prophylaxis of VTE in the trauma patient population in terms of efficacy, safety, and cost. There is no difference between LDUH and LMWH for VTE prophylaxis. Four databases were utilized to find 9 relevant studies whose patient population was adult trauma patients: PubMed, CINAHL, EMBASE and Scopus. Two studies found statistically significant differences in deep venous thrombosis, and 3 found differences in pulmonary embolism between LDUH and LMWH. Only 1 study demonstrated a significant difference in bleeding complications between the 2 treatment regimens. Two statedthat using LDUH resulted in remarkable cost savings versus LMWH. The 9 studies all came to different conclusions. Contrary findings may have been affected by population variety, different dosing regimens, various applications of mechanical VTE prophylaxis, and/or different VTE-screening tools. All of the studies had major variances leading to conflicting results, which made this review unable to draw concrete conclusions. Limitations of each study, population variety, and disparity of dosing regimens made it difficult for this review to make recommendations for practice. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
3. Clinical and financial evaluation of carbetocin as postpartum haemorrhage prophylaxis at caesarean section: A retrospective cohort study.
- Author
-
Wohling, Jemma, Edge, Nicole, Pena‐Leal, David, Wang, Rui, Mol, Ben Willem, and Dekker, Gustaaf
- Subjects
- *
OXYTOCICS , *BLOOD diseases , *CESAREAN section , *CHI-squared test , *CONFIDENCE intervals , *HEMORRHAGE , *LONGITUDINAL method , *MULTIVARIATE analysis , *PREGNANCY complications , *PUERPERAL disorders , *STATISTICS , *WOMEN'S health , *COST analysis , *DATA analysis , *TREATMENT effectiveness , *RETROSPECTIVE studies , *DATA analysis software , *ODDS ratio , *EVALUATION , *THERAPEUTICS - Abstract
Background: The long‐acting oxytocic agent; carbetocin, has been consistently shown to reduce the need for additional uterotonics at caesarean section, but not postpartum haemorrhage (PPH). While promising, current evidence is limited by heterogenicity in study design and findings. Aims: To examine whether carbetocin confers clinical or economic benefit compared to oxytocin at caesarean section in an all‐risk Australian population. Materials and Methods: A retrospective cohort study was undertaken of all singleton caesarean sections at a public tertiary hospital from 2008 to 2010 (n = 2499). From 1 January 2008 to 24 March 2009 all women received prophylactic oxytocin 5–10 units slow push intravenously at delivery, after which all patients received 100 μg intravenous carbetocin. Outcomes were PPH (≥1000 mL) and the requirement of secondary uterotonics. A post hoc cost analysis was also performed. Results: A total of 1467 and 1024 patients received carbetocin and oxytocin, respectively. Incidence of PPH ≥1000 mL was 7.8% for carbetocin compared to and 9.7% for oxytocin (odds ratio (OR) 0.79, 95% CI 0.59–1.05). Moderate blood loss >500 mL was significantly reduced with carbetocin; occurring in 27.3% versus 39.4% (OR 0.57, 95% CI 0.49–0.68). There was a 20.0% reduction in secondary uterotonic treatment with carbetocin (OR 0.42, 95% CI 0.35–0.49). Average drug costs were lower with oxytocin at $4.74 versus $36.42/patient. However, the 1.9% reduction in PPH with carbetocin resulted in a $63.46 reduction in cost per patient, with a cost‐effectiveness ratio of $1667 to prevent one case of PPH ≥1000 mL. Conclusions: Carbetocin reduced moderate blood loss >500 mL, but not PPH ≥1000 mL. Carbetocin conferred a 20% reduction in secondary uterotonic treatment, as well as lowering direct medical costs. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
4. New Options in the Treatment of Hepatitis C (HCV): Economic and Clinical Consideration for Improved Patient Outcomes.
- Author
-
Sulkowski, Mark S.
- Subjects
HEPATITIS C prevention ,HEPATITIS C treatment ,NUCLEOTIDES ,THERAPEUTIC use of protease inhibitors ,ANTIVIRAL agents ,COMBINATION drug therapy ,INFECTIOUS disease transmission ,CLINICAL pathology ,HEPATITIS C ,MEDICAL protocols ,MEDICAL screening ,PROFESSIONAL associations ,HEALTH insurance reimbursement ,COST analysis ,SOCIOECONOMIC factors ,TREATMENT effectiveness ,DISEASE prevalence ,PATIENT selection ,PARENTERAL infusions ,GENOTYPES ,THERAPEUTICS - Abstract
Very effective therapies are available to cure hepatitis C viral (HCV) infections. People should be screened according to the guidelines and offered treatment once diagnosed. Curing HCV is not only cost effective, it is cost saving. [ABSTRACT FROM AUTHOR]
- Published
- 2019
5. Short-term results of the efficacy of percutaneous tibial nerve stimulation on urinary symptoms and its financial cost.
- Author
-
Kurdoğlu, Zehra, Carr, Danielle, Harmouche, Jihad, Ünlü, Serdar, and Kılıç, Gökhan S.
- Subjects
- *
DRUG therapy , *MEDICAL care costs , *NEURAL stimulation , *TIBIAL nerve , *URINATION , *VAGUS nerve , *COST analysis , *TREATMENT effectiveness , *PRE-tests & post-tests , *DESCRIPTIVE statistics , *OVERACTIVE bladder , *SYMPTOMS , *ECONOMICS , *THERAPEUTICS - Abstract
Objective: Overactive bladder (OAB) affects 16.9% of women in the United States. Percutaneous tibial nerve stimulation (PTNS) is a thirdline treatment for patients who are refractory to behavioral and pharmacologic therapies. We aimed to evaluate the effects of PTNS on urinary symptoms in patients diagnosed as having refractory OAB and investigate the cost of medications and clinical visits before and after PTNS treatment. Material and Methods: We reviewed 60 women with refractory OAB treated with PTNS. Episodes of urinary frequency, leakage, urgency, and nocturia; number of follow-up visits; and medications were recorded. The mean quarterly drug, physician, nurse, and provider costs were calculated. The episodes of urinary symptoms, numbers of follow-up visits, and costs of medications and visits before and after PTNS were compared. Results: Of the 60 patients with refractory OAB, 24 patients who completed 12 weekly sessions of initial PTNS were evaluated. The number of urinary symptoms and follow-up visits significantly decreased after PTNS (p<0.05). The average quarterly medication cost decreased from $656.36±292.45 to $375.51±331.79 after PTNS (p=0.001). After PTNS, quarterly physician and nurse visit costs decreased from $81.73±70.39 to $25.89±54.40 and from $55.23±38.32 to $15.53±19.58, respectively (p<0.05). The quarterly total provider cost was similar before and after PTNS. Conclusion: PTNS treatment significantly improved urinary symptoms of patients with refractory OAB and reduced the costs of medications and physician and nurse visits. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
6. A standardized stepwise drug treatment algorithm for depression reduces direct treatment costs in depressed inpatients - Results from the German Algorithm Project (GAP3).
- Author
-
Ricken, Roland, Wiethoff, Katja, Reinhold, Thomas, Stamm, Thomas J., Baghai, Thomas C., Fisher, Robert, Seemüller, Florian, Brieger, Peter, Cordes, Joachim, Laux, Gerd, Hauth, Iris, Möller, Hans-Jürgen, Heinz, Andreas, Bauer, Michael, and Adli, Mazda
- Subjects
- *
STEPWISE reactions (Chemistry) , *MEDICAL care standards , *MEDICAL care cost control , *MENTAL depression , *THERAPEUTICS , *HOSPITAL care , *ALGORITHMS , *ANTIDEPRESSANTS , *COST effectiveness , *MEDICAL care costs , *MEDICAL protocols , *WEIGHTS & measures , *COST analysis , *TREATMENT effectiveness , *ECONOMICS - Abstract
Background: In a previous single center study we found that a standardized drug treatment algorithm (ALGO) was more cost effective than treatment as usual (TAU) for inpatients with major depression. This report aimed to determine whether this promising initial finding could be replicated in a multicenter study.Methods: Treatment costs were calculated for two time periods: the study period (from enrolment to exit from study) and time in hospital (from enrolment to hospital discharge) based on daily hospital charges. Cost per remitted patient during the study period was considered as primary outcome.Results: 266 patients received ALGO and 84 received TAU. For the study period, ALGO costs were significantly lower than TAU (ALGO: 7 848 ± 6 065 €; TAU: 10 033 ± 7 696 €; p = 0.04). For time in hospital, costs were not different (ALGO: 14 734 ± 8 329 €; TAU: 14 244 ± 8 419 €; p = 0.617). Remission rates did not differ for the study period (ALGO: 57.9%, TAU: 50.0%; p=0.201). Remission rates were greater in ALGO (83.3%) than TAU (66.2%) for time in hospital (p = 0.002). Cost per remission was lower in ALGO (13 554 ± 10 476 €) than TAU (20 066 ± 15 391 €) for the study period (p < 0.001) and for time in hospital (ALGO: 17 582 ± 9 939 €; TAU: 21 516 ± 12 718 €; p = 0.036).Limitations: Indirect costs were not assessed. Different dropout rates in TAU and ALGO complicated interpretation.Conclusions: Treatment algorithms enhance the cost effectiveness of the care of depressed inpatients, which replicates our prior results in an independent sample. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
7. Rivaroxaban vs. warfarin on extended deep venous thromboembolism treatment: A cost analysis.
- Author
-
Diken, Adem İ, Yalçınkaya, Adnan, Hanedan, Muhammet O., Erol, Mehmet E., and Ercen Diken, Özlem
- Subjects
- *
ANTICOAGULANTS , *HEMORRHAGE complications , *DRUG therapy , *COMPARATIVE studies , *LENGTH of stay in hospitals , *VENOUS thrombosis , *WARFARIN , *COST analysis , *TREATMENT effectiveness , *RETROSPECTIVE studies , *TREATMENT duration , *INTERNATIONAL normalized ratio , *RIVAROXABAN , *THERAPEUTICS - Abstract
Background Standard treatment for deep venous thromboembolism involves parenteral anticoagulation overlapping with a vitamin K antagonist, an approach that is effective but associated with limitations including the need for frequent coagulation monitoring. The direct oral anticoagulant rivaroxaban is similarly effective to standard therapy as a single-drug treatment for venous thromboembolism and does not require routine coagulation monitoring. The aim of this analysis was to project the long-term costs and outcomes for rivaroxaban compared to standard of care (tinzaparin/warfarin). Methods A total of 184 patients who were under anticoagulant therapy with warfarin or rivaroxaban for extended deep venous thromboembolism were retrospectively evaluated; 59 received rivaroxaban and 125 received warfarin therapy. Assessments were made on age, gender, place of residence, the duration of anticoagulation, mean international normalized ratio value, the effective rate of international normalized ratio (time in the therapeutic range), bleeding-related complication rate, duration of hospitalization due to complications, the number of annual outpatient department admission, cost for drug, cost for hospitalization, cost for outpatient department admission and international normalized ratio measurements. Results The annual outpatient cost is higher in warfarin group (147.09 ± 78 vs. 62.32 ± 19.79 USD p < 0.001). But annual drug cost is higher in rivaroxaban group (362.6 vs. 71.55 ± 31.01 USD p < 0.001). Overall cost of rivaroxaban group is higher than warfarin group (476.25 ± 36.78 vs. 364.82 ± 174.44 USD). Warfarin is not cost-effective when non-drug costs (342.5 ± 174.44 vs. 113.65 ± 36.77) and hospital costs (173.85 ± 122.73 vs. 64.9 ± 23.55 USD) were analyzed. Conclusion This analysis suggests that rivaroxaban has lower costs than warfarin in terms of outpatient department admission and hospital costs due to complications; however, warfarin was more economic when all cost parameters were considered. Time in the therapeutic range was found as 56% for warfarin that should be taken into account while analyzing costs and benefits. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
8. Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer.
- Author
-
Franken, M.D., van Rooijen, E.M., May, A.M., Koffijberg, H., van Tinteren, H., Mol, L., ten Tije, A.J., Creemers, G.J., van der Velden, A.M.T., Tanis, B.C., Uyl-de Groot, C.A., Punt, C.J.A., Koopman, M., and van Oijen, M.G.H.
- Subjects
- *
BEVACIZUMAB , *OXALIPLATIN , *THERAPEUTIC use of antimetabolites , *ANTINEOPLASTIC agents , *COLON tumors , *METASTASIS , *QUALITY of life , *QUESTIONNAIRES , *SURVIVAL , *COST analysis , *TREATMENT effectiveness , *QUALITY-adjusted life years , *THERAPEUTICS ,RECTUM tumors - Abstract
Aim Capecitabine and bevacizumab (CAP-B) maintenance therapy has shown to be more effective compared with observation in metastatic colorectal cancer patients achieving stable disease or better after six cycles of first-line capecitabine, oxaliplatin, bevacizumab treatment in terms of progression-free survival. We evaluated the cost-effectiveness of CAP-B maintenance treatment. Methods Decision analysis with Markov modelling to evaluate the cost-effectiveness of CAP-B maintenance compared with observation was performed based on CAIRO3 study results (n = 558). An additional analysis was performed in patients with complete or partial response. The primary outcomes were the incremental cost-effectiveness ratio (ICER) defined as the additional cost per life year (LY) and quality-adjusted life years (QALY) gained, calculated from EQ-5D questionnaires and literature and LYs gained. Univariable sensitivity analysis was performed to assess the influence of input parameters on the ICER, and a probabilistic sensitivity analysis represents uncertainty in model parameters. Results CAP-B maintenance compared with observation resulted in 0.21 QALYs (0.18LYs) gained at a mean cost increase of €36,845, yielding an ICER of €175,452 per QALY (€204,694 per LY). Varying the difference in health-related quality of life between CAP-B maintenance and observation influenced the ICER most. For patients achieving complete or partial response on capecitabine, oxaliplatin, bevacizumab induction treatment, an ICER of €149,300 per QALY was calculated. Conclusion CAP-B maintenance results in improved health outcomes measured in QALYs and LYs compared with observation, but also in a relevant increase in costs. Despite the fact that there is no consensus on cost-effectiveness thresholds in cancer treatment, CAP-B maintenance may not be considered cost-effective. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
9. Financial and clinical outcomes of extracorporeal mechanical support.
- Author
-
Chiu, Ryan, Pillado, Eric, Sareh, Sohail, De La Cruz, Kim, Shemin, Richard J., and Benharash, Peyman
- Subjects
- *
CARDIOPULMONARY resuscitation , *RESPIRATORY insufficiency , *CARDIOGENIC shock , *EXTRACORPOREAL membrane oxygenation , *HEART diseases , *HOSPITAL charges , *SURVIVAL , *TIME , *TREATMENT effectiveness , *RETROSPECTIVE studies , *ECONOMICS , *THERAPEUTICS ,RESPIRATORY insufficiency treatment - Abstract
Background: Over the past decade, extracorporeal mechanical support (ECMO) has been increasingly utilized in respiratory failure and cardiogenic shock. There is a need for assessing clinical and financial outcomes of ECMO use. This study presents our institution's experience with veno-arterial ECMO (VA-ECMO) over a 9-year period.Methods: A retrospective review of our institution's ECMO database identified patients undergoing VA-ECMO between 2005 and 2013 (N = 150). Patients were assigned to four groups by indication: post-cardiotomy syndrome, cardiogenic shock requiring cardiopulmonary resuscitation (CPR), cardiogenic shock not requiring CPR, and respiratory failure. Hospital charges from administrative records were analyzed. Trend and correlation analyses were used to evaluate clinical and financial outcomes.Results: Of the 150 patients meeting inclusion criteria, 28% required VA-ECMO for post-cardiotomy syndrome, 31.3% for cardiogenic shock with CPR, 35.3% for cadiogenic shock with no CPR, and 5.4% for respiratory failure. Mean duration on ECMO was 5.0 ± 3.4 days with a survival rate of 64% and no difference between the four groups (p = 0.40). ECMO-associated charges averaged $74,500 ± 61,400 per patient, 6% of total hospital charges. Subgroup analysis of cardiogenic shock patients revealed a nearly twofold increase in ECMO-related charges among patients who did not receive CPR (p = 0.04), as well as a trend toward improved survival (69.8% vs 51.1%, p = 0.06).Conclusion: In view of the variations in survival and costs in ECMO patients, further studies should aim to delineate patient populations that benefit from early initiation of ECMO. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
10. A retrospective comparison of robotic cholecystectomy versus laparoscopic cholecystectomy: operative outcomes and cost analysis.
- Author
-
Strosberg, David, Nguyen, Michelle, Muscarella, Peter, Narula, Vimal, Strosberg, David S, Nguyen, Michelle C, Muscarella, Peter 2nd, and Narula, Vimal K
- Subjects
- *
SURGICAL robots , *CHOLECYSTECTOMY , *GALLBLADDER surgery , *CHOLECYSTITIS , *GALLBLADDER diseases , *THERAPEUTICS , *BILE duct diseases , *CHOLANGIOGRAPHY , *CHRONIC diseases , *COMPARATIVE studies , *GALLSTONES , *LAPAROSCOPIC surgery , *RESEARCH methodology , *MEDICAL cooperation , *RESEARCH , *SURGICAL complications , *OPERATIVE surgery , *COST analysis , *EVALUATION research , *TREATMENT effectiveness , *RETROSPECTIVE studies , *CHOLANGITIS , *ECONOMICS - Abstract
Introduction: Robotic-assisted surgery is gaining popularity in general surgery. Our objective was to evaluate and compare operative outcomes and total costs for robotic cholecystectomy (RC) and laparoscopic cholecystectomy (LC).Methods and Procedures: A retrospective review was performed for all patients who underwent single-procedure RC and LC from January 2011 to July 2015 by a single surgeon at a large academic medical center. Demographics, diagnosis, perioperative variables, postoperative complications, 30-day readmissions, and operative and hospital costs were collected and analyzed between those patient groups.Results: A total of 237 patients underwent RC or LC, and comprised the study population. Ninety-seven patients (40.9 %) underwent LC, and 140 patients (50.1 %) underwent RC. Patients who underwent RC had a higher body mass index (p = 0.03), lower rates of coronary artery disease (p < 0.01), and higher rates of chronic cholecystitis (p < 0.01). There were lower rates of intraoperative cholangiography (p < 0.01) and conversion to an open procedure (p < 0.01), however longer operative times (p < 0.01) for patients in the RC group. There were no bile duct injuries in either group, no difference in bile leak rates (p = 0.65), or need for reoperation (p = 1.000). Cost analysis of outpatient-only procedures, excluding cases with conversion to open or use of intraoperative cholangiography, demonstrated higher total charges (p < 0.01) and cost (p < 0.01) and lower revenue (p < 0.01) for RC compared to LC, with no difference in total payments (p = 0.34).Conclusions: Robotic cholecystectomy appears to be safe although costlier in comparison with laparoscopic cholecystectomy. Further studies are needed to understand the long-term implications of robotic technology, the cost to the health care system, and its role in minimally invasive surgery. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
11. Comparison of efficacy and cost of three different antimicrobial prophylaxis drugs in microsurgical transsphenoidal surgery.
- Author
-
Ulutabanca, Halil, Kilic, Aysegul Ulu, Alp, Emine, Orhan, Tülay, Selçuklu, Ahmet, and Doganay, Mehmet
- Subjects
STEROID drugs ,STEROIDS ,SURGICAL site infection prevention ,COMPARATIVE studies ,MICROSURGERY ,NEUROSURGERY ,PITUITARY diseases ,COST analysis ,CEFAZOLIN ,TREATMENT effectiveness ,RETROSPECTIVE studies ,ANTIBIOTIC prophylaxis ,CEFTRIAXONE ,ECONOMICS ,THERAPEUTICS - Abstract
Background: While some elective neurosurgery operations, such as craniotomy, cerebrospinal fluid shunting procedures and intrathecal pumps, have clear recommendations for antimicrobial prophylaxis (AMP), no comprehensive recommendations exist for transsphenoidal surgery (TSS). The aim of this study was to compare the efficacy and cost of three different AMP drugs in TSS. Method: A retrospective analysis of the clinical records of patients who underwent pituitary surgery between January 2012 and February 2016 was performed. TSS was performed via endonasal microsurgical approach. Patients were classified into three groups according to AMP regimen received. The cost analysis per patient was calculated in United States dollars. Results: We identified a total of 126 patients who underwent TSS. Of these, 32 (25.3%) received chemoprophylaxis with cefazolin, 50 (39.6%) with ceftriaxone, and 44 (34.9%) with fucidic acid drops. There were no cases of peri- or post-operative meningitis or any other procedure-associated infections in these patients. Cost-comparison of the three AMP regimens showed that cefazolin was more expensive than ceftriaxone and fusidic acid regimens. Conclusion: Three compared AMP drugs for TSS were found similarly effective with no reported infectious complication. The requirement of AMP for TSS is still controversial at hospitals where the infection rate is very low and the majority of infections are treatable. [ABSTRACT FROM AUTHOR]
- Published
- 2017
12. Economic evaluation of artesunate and three quinine regimens in the treatment of severe malaria in children at the Ebolowa Regional Hospital-Cameroon: a cost analysis.
- Author
-
Ethe Maka, Daniel, Chiabi, Andreas, Obadeyi, Bolaji, Mah, Evelyn, Nguefack, Séraphin, Nana, Pamela, Mbacham, Wilfred, and Mbonda, Elie
- Subjects
- *
DRUG therapy for malaria , *QUININE , *HOSPITAL care , *ROUTINE diagnostic tests , *ANTIMALARIALS , *CHI-squared test , *NURSING , *STATISTICAL sampling , *COST analysis , *TREATMENT effectiveness , *DATA analysis software , *ECONOMICS , *THERAPEUTICS - Abstract
Background: Severe malaria is a leading cause of morbidity and mortality in under-fives in sub-Saharan Africa. Recently quinine has been replaced by artesunate as the first-line drug in the treatment of severe malaria in Cameroon. Artesunate has been shown to be cost-effective in African children, but whether these findings are transferable to Cameroonian children remains to be explored. Objectives: To conduct a cost-analysis of four different regimens used in the treatment from the perspective of the healthcare payer. Methods: An economic evaluation alongside a randomized comparative study was conducted in children aged 3 months to 15 years, admitted at the Ebolowa Regional Hospital with severe malaria due to Plasmodium falciparum. Patients were randomized to receive one of the four treatment alternatives. Group 1 (ARTES) received parenteral artesunate at 2.4 mg/kg at H0, H12, H24 and then once daily; Group 2 (QLD) received a loading dose of quinine base at 16.6 mg/kg followed 8 h later by an 8-hourly maintenance dose of 8.3 mg/kg quinine base; Group 3 (QNLD3) received 8.3 mg/kg quinine base every 8 h, and Group 4 (QNLD2) received 12.5 mg/kg quinine base every 12 h. The main outcome measure for effectiveness of treatment was the parasite reduction rate. Based on a healthcare perspective, an evaluation of direct medical costs was done, including costs of anti-malarials, nursing care materials, adjuvant treatment, laboratory investigations, hospitalisation and professional fees. Guided by a cost minimalization approach, the relative costs of these treatment alternatives was compared and reported. Results: Overall cost was higher for ARTES group at $65.14 (95% CI $57.68-72.60) than for quinine groups ($52.49-$62.40), but the difference was not statistically significant. Cost of the anti-malarial drug was significantly higher for artesunate-treated patients than for quinine-treated patients, whereas cost of hospitalization was significantly lower for artesunate-treated patients than for quinine-treated patients. Incremental analysis of ARTES against QLD as a baseline resulted in an ICER of $46.8/PRR24 and suggests ARTES as the most cost effective of all four treatment options. Conclusion: Artesunate is a cost effective malaria treatment option relative to quinine alternatives with the lowest incremental cost per unit of effectiveness. Trial registration clinicaltrials.gov identifier: NCT02563704. Registered 19 September 2015, retrospectively registered [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
13. Cost-effectiveness, in a randomized trial, of glass-ionomer-based and resin sealant materials after 4 yr.
- Author
-
Goldman, Ann S., Chen, Xi, Fan, Mingwen, and Frencken, Jo E.
- Subjects
- *
PIT & fissure sealants (Dentistry) , *CLINICAL medicine , *EVALUATION of medical care , *RESEARCH funding , *WORLD health , *COST analysis , *RANDOMIZED controlled trials , *TREATMENT effectiveness , *KAPLAN-Meier estimator , *THERAPEUTICS - Abstract
This study, conducted from a government program perspective, compared the incremental cost-effectiveness of oral health interventions, in particular their delivery to underserved populations in whom dental sealants constitute an important, high-yielding complement to toothbrushing in dental-caries prevention. The study data concern the relative cost-effectiveness of three sealant materials in four approaches to prevent cavitated dentine carious lesions in permanent molars in a community intervention trial among school-age children in Wuhan, China. The four approaches were high-viscosity glass-ionomer cement without heat application ( HVGIC); high-viscosity glass-ionomer cement with heat application [light-emitting diode ( LED) thermocured HVGIC]; glass-carbomer; and composite resin. The costs studied were: cost of sealing permanent molars; adverse event costs for restoring cavitated dentine carious lesions developing within 4 yr in study data; and projections of 1,000 sealants per group. Preventing one more cavitated dentine carious lesion cost US$105 for the study data when comparing HVGIC ( n = 405) with composite resin ( n = 396) and US$59 per 1,000 sealants in the projections; LED thermocured HVGIC compared with composite resin cost US$115 for one more cavitated lesion and US$52 per 1,000 sealants, respectively. Although more expensive than composite resin, LED thermocured HVGIC was identified as the most cost-effective among the sealant materials studied. Ease of application, minimal technical and infrastructure requirements, and cost-effectiveness make glass-ionomers a practicable option for governments making decisions under economic constraints. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
14. Home Oxygen Therapy Devices: Providing the Prescription.
- Author
-
Branson, Richard D., King, Angela, and Giordano, Sam P.
- Subjects
OBSTRUCTIVE lung disease treatment ,OXYGEN therapy equipment ,HYPOXEMIA ,HOME care services ,LONG-term health care ,MEDICAL equipment ,NEEDS assessment ,OXYGEN therapy ,SERIAL publications ,COST analysis ,PRODUCT design ,TREATMENT effectiveness ,THERAPEUTICS ,EQUIPMENT & supplies - Abstract
The article discusses a study that examined portable oxygen concentrators (POCs) in a model of the respiratory system and using mathematical modeling. The study confirmed the ability of pulse-dose oxygen to maximize oxygen delivery to alveolar units. The concerns on POCs, the prescription for oxygen, and confusion among caregivers and patients over what a POC setting represents are noted.
- Published
- 2019
- Full Text
- View/download PDF
15. Fluticasone furoate/Vilanterol 92/22 μg once-a-day vs Beclomethasone dipropionate/ Formoterol 100/6 μg b.i.d.: a 12-week cost analysis in mild-to-moderate asthma.
- Author
-
Negro, Roberto W. Dal, Distante, Chiara, Bonadiman, Luca, Turco, Paola, and Iannazzo, Sergio
- Subjects
- *
FLUTICASONE , *BECLOMETHASONE dipropionate , *FORMOTEROL , *ASTHMA treatment , *COMBINATION drug therapy , *MEDICAL care costs , *TREATMENT effectiveness , *THERAPEUTICS - Abstract
Background: Asthma is a disease with high cost for the National Health Service. Two of the most recent LABA/ICS combinations for persistent bronchial asthma are Beclomethasone dipropionate/Formoterol (B/F) delivered via the Nexthaler device and Fluticasone furoate/Vilanterol (F/V) delivered via the Ellipta device. No comparison has been carried out yet in terms of cost analysis in asthma, to our knowledge. Aim of the present monocentric, observational, retrospective study was to calculate and compare the costs of mild-to-moderate asthma patients assuming B/F 100/6 μg b.i.d. to those of patients assuming F/V 92/22 μg once-a-day over a 12-week treatment period from the Italian National Health Service perspective. Methods: Data were obtained automatically and anonymously from the institutional database of the Lung Unit of the Specialist Medical Centre (CEMS), Verona, Italy, UNI EN ISO 9001-2008 validated. FEV1 values, number of relapses, healthcare resources as hospitalizations due to asthma relapses, days of hospitalization, general practitioner (GP), specialist visits, and days of inactivity, were recorded over the study period together with the use of extra medications (systemic steroids and antibiotics). In order to compare the outcomes achieved in both groups, the propensity score matching method was used in STATA, and statistical significance was accepted for p < 0.05. Results: Clinical data of 77 patients treated with B/F b.i.d (Group A) and of 40 patients treated with F/V 92/22 μg once-a-day (Group B) were selected. The PS-matching process, designed as matching on the baseline covariates, gender, age, FEV1 and comorbidities, returned a cohort of 40 group A patients of the entire cohort matched with 40 patients of group B, fully comparable for demographics and clinical characteristics. In the PS-matched cohort, the mean (±SE) number of relapses per patient during the follow-up was 0.53 (±0.12) in group A and 0.28 (±0.07) in group B. In group A, n = 25 (62.50%), n = 9 (22.50%), and n = 6 (15%) patients had 0, 1, 2 relapses, respectively. In group B, n=29 (72.50%), and n = 11 (27.50%) had 0 and 1 relapse, respectively. Over the study period, the average number of hospitalizations per patient was 0.15 (±0.06), with 0.28 (±0.12) days of hospitalization in group A, and 0.08 (±0.04) with 0.08 (±0.04) days of hospitalization in group B, respectively. The difference between the two groups in terms of FEV1(L) improvement vs baseline was 0.11 in favour of group B (p = 0.007). When results were compared, the improvement in lung function obtained in group B proved significantly higher both in terms of absolute FEV1 and of FEV1% predicted. The mean (±SE) cost of hospitalizations per patient was € 345.30 (±133.23) in group A and € 172.65 (±98.18) in group B, respectively, with a mean not significant difference of - € 172.65 in favour of group B (p = 0.9). In particular, the mean (±SE) cost for visits per patient was € 26.82 (±3.73) in group A and € 11.36 (±2.30) in group B (p = 0.002), and the mean cost for rescue medications per patient was € 35.24 (±6.93) in group A, and € 18.73 (±3.38) in group B, respectively (p = 0.05). Conclusions: Even if both ICS/LABA combinations were checked over a limited period of time, they seem characterized by a different profile in terms of effect on lung function and economic impact on mild-tomoderate asthma. The once-daily inhalation of combined Fluticasone furoate/Vilanterol 92/22 μg showed the potential for enhanced clinical outcomes and reduced costs when compared to Beclomethasone dipropionate/Formoterol 100/6 μg b.i.d. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
16. Economic analysis of insulin initiation by pharmacists in a Canadian setting.
- Author
-
Brown, Stephen, Al Hamarneh, Yazid N., Tsuyuki, Ross T., Nehme, Kimberley, and Sauriol, Luc
- Subjects
COST control ,COST effectiveness ,INSULIN derivatives ,TYPE 2 diabetes ,PHARMACISTS ,QUALITY of life ,SURVIVAL ,COST analysis ,TREATMENT effectiveness ,EARLY medical intervention ,STATISTICAL models ,GLYCEMIC control ,ECONOMICS ,THERAPEUTICS - Abstract
Background: Conducted in Alberta, the RxING study examined the effect of a community pharmacist prescribing intervention on glycemic control in patients with uncontrolled type 2 diabetes mellitus (T2DM) using insulin glargine. The objective of this study was to assess the cost-effectiveness of pharmacists’ prescribing of insulin glargine as an early intervention in uncontrolled patients with T2DM vs usual clinical practice. Methods: The IMS CORE diabetes Markov model was used to project long-term clinical outcomes, costs and cost-effectiveness of interventions. The efficacy of insulin glargine, in terms of hemoglobin A1c reduction and hypoglycemia rates, was obtained from the RxING study. Health utility and cost data were found in Canadian publications. The base-case analyses examined the economic and clinical effects of having pharmacists initiate insulin therapy in patients with uncontrolled T2DM in comparison to a physician initiate it up to 3 years later. Results: Insulin initiation by pharmacists with uncontrolled T2DM patients is cost-effective. Having pharmacists prescribe insulin 1 year earlier than usual clinical practice resulted in an incremental cost savings of $805 (CDN$) and a gain of 0.048 QALYs per patient. Pharmacists prescribing insulin 2 years earlier resulted in an incremental cost savings of $624 (CDN$) per year and a gain of 0.075 quality-adjusted life-years (QALYs). Prescribing 3 years earlier allowed for a minor increase of $26 and a gain of 0.086 QALYs. Conclusion: Earlier initiation of insulin by pharmacists, in uncontrolled T2DM patients, resulted in cost savings and delays in the development of diabetes-related complications, leading to an improved quality of life and increased survival rates. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
17. An economic evaluation of outpatient versus inpatient polyp treatment for abnormal uterine bleeding.
- Author
-
Diwakar, L, Roberts, TE, Cooper, NAM, Middleton, L, Jowett, S, Daniels, J, Smith, P, and Clark, TJ
- Subjects
- *
POLYPS , *UTERINE hemorrhage treatment , *ENDOMETRIAL diseases , *HYSTEROSCOPY , *OUTPATIENT medical care research , *COST effectiveness , *THERAPEUTICS , *COMPARATIVE studies , *OUTPATIENT medical care , *GYNECOLOGIC surgery , *HOSPITAL care , *RESEARCH methodology , *MEDICAL care research , *MEDICAL care costs , *MEDICAL cooperation , *PATIENT satisfaction , *RESEARCH , *UTERINE hemorrhage , *COST analysis , *EVALUATION research , *RANDOMIZED controlled trials , *TREATMENT effectiveness , *DISEASE complications , *SURGERY , *ECONOMICS - Abstract
Objectives: To undertake a cost-effectiveness analysis of outpatient uterine polypectomy compared with standard inpatient treatment under general anaesthesia.Design: Economic evaluation carried out alongside the multi-centre, pragmatic, non-inferiority, randomised controlled Outpatient Polyp Treatment (OPT) trial. The UK National Health Service (NHS) perspective was used in the estimation of costs and the interpretation of results.Setting: Thirty-one secondary care UK NHS hospitals between April 2008 and July 2011.Participants: Five hundred and seven women with abnormal uterine bleeding and hysteroscopically diagnosed endometrial polyps.Interventions: Outpatient uterine polypectomy versus standard inpatient treatment. Clinicians were free to choose the technique for polypectomy within the allocated setting.Main Outcome Measures: Patient-reported effectiveness of the procedure determined by the women's self-assessment of bleeding at 6 months, and QALY gains at 6 and 12 months.Results: Inpatient treatment was slightly more effective but more expensive than outpatient treatment, resulting in relatively high incremental cost-effectiveness ratios. Intention-to-treat analysis of the base case at 6 months revealed that it cost an additional £9421 per successfully treated patient in the inpatient group and £ 1,099,167 per additional QALY gained, when compared with outpatient treatment. At 12 months, these costs were £22,293 per additional effectively treated patient and £445,867 per additional QALY gained, respectively.Conclusions: Outpatient treatment of uterine polyps associated with abnormal uterine bleeding appears to be more cost-effective than inpatient treatment at willingness-to-pay thresholds acceptable to the NHS.Tweetable Abstract: HTA-funded OPT trial concluded that outpatient uterine polypectomy is cost-effective compared with inpatient polypectomy. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
18. Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia.
- Author
-
McGarry, Lisa J., Chen, Yaozhu J., Divino, Victoria, Pokras, Shibani, Taylor, Catherine R., Munakata, Julie, Nieset, Christopher C., Huang, Hui, Jabbour, Elias, and Malone, Daniel C.
- Subjects
- *
MYELOID leukemia , *LEUKEMIA treatment , *PROTEIN-tyrosine kinase inhibitors , *MEDICAL care costs , *HOSPITAL care , *MEDICAL databases , *THERAPEUTICS , *PROTEIN kinase inhibitors , *DATABASES , *PROTEIN-tyrosine kinases , *REGRESSION analysis , *COST analysis , *CHRONIC myeloid leukemia , *TREATMENT effectiveness , *RETROSPECTIVE studies , *CHEMICAL inhibitors , *ECONOMICS - Abstract
Objective: To assess the economic burden of tyrosine kinase inhibitor (TKI) treatment failure in chronic myeloid leukemia (CML), by assessing all-cause health care resource use (HCRU) and costs in the year after treatment failure by line of therapy (LOT; 1L/2L/3L) using real-world data.Methods: Treatment episodes initiating a TKI of interest (index TKI) during June 2008-December 2011 were identified from the IMS PharMetrics Plus Health Plan Claims Database for adult patients with CML diagnosis (ICD-9-CM 205.1x), 120 days pre-index continuous enrollment (CE) and no clinical trial participation. Episodes experiencing treatment failure, defined as switch to a non-index TKI or discontinuation of index TKI (gap of ≥ 60 days), and with 1 year CE post-failure, were analyzed. LOT was determined by number of unique TKIs used in the pre-index. All-cause HCRU and costs (2012 USD) in the 1 year post-failure were assessed by LOT, and the comparisons between 1L and 2L failures were also adjusted using multivariate generalized linear models (GLMs) to control for underlying differences.Results: A total of 706 episodes were identified (518 1L; 180 2L; 8 3L). Unadjusted HCRU over 1 year post-failure increased significantly. This was accompanied by a significant increase in unadjusted mean costs for 2L failures vs. 1L failures ($99,624 vs. $78,667, p = 0.021, Δ$20,957). Following the adjustment using GLMs, adjusted mean costs were 38% higher (95% CI 1.14-1.68), driven primarily by use of medical services. In adjusted analyses, compared to 1L, 2L failures had: 45% more ambulatory visits (mean 31 vs. 21, 95% CI 1.26-1.66), 75% higher risk of hospitalization (33% vs. 23% hospitalized, 95% CI 1.16-2.64), and 73% higher medical costs (95% CI 1.31-2.29). Medical costs comprised a greater proportion of total costs in 2L vs. 1L (55% vs. 44%); pharmacy costs did not increase significantly.Conclusions: The economic burden over 1 year post TKI failure increased with each sequential line of TKI treatment failure. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
19. Analysis of the efficiency and costs of antifungal prophylaxis and mycological diagnostics in patients undergoing allogeneic haematopoietic cell transplantation: "real life" evaluation.
- Author
-
Bertz, Hartmut, Drognitz, Kathrin, Finke, Jürgen, and Finke, Jürgen
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *FLUCONAZOLE , *ANTIFUNGAL agents , *MEDICAL care costs , *COST effectiveness , *DIAGNOSTIC services , *THERAPEUTICS , *DIAGNOSIS , *COMPARATIVE studies , *HOMOGRAFTS , *IMMUNOSUPPRESSION , *LONGITUDINAL method , *RESEARCH methodology , *MEDICAL cooperation , *MYCOSES , *PREVENTIVE health services , *RESEARCH , *EVALUATION research , *TREATMENT effectiveness , *ECONOMICS - Abstract
Antifungal prophylaxis/therapy (AP/AT) raises the cost of allogeneic haematopoietic cell transplantation (alloHCT). Its efficacy, different approaches for AP/AT, diagnostic measures and cost-effectiveness must still be evaluated. In 2010, we conducted a prospective study with 106 consecutive patients receiving an alloHCT analysing AP/AT, choice and costs of diagnostics applied including CT scans, galactomannan (Gal) and β-D-glucan (β-D) testing. Antifungal prophylaxis in 91 patients consisted of fluconazole (FLU) or L-AMB (AmBisome™ 1 or 3 mg/kg/day b.w.), and antifungal therapy had to be initiated in 38 % of the FLU/L-AMB-1-mg patients but in none with L-AMB 3 mg. Empirical AT consisted of L-AMB 1 mg/kg (n = 12) and preemptive AT of L-AMB 3 mg/kg (n = 17) and proved very efficacious with no further antifungal drug escalation in 89.6 %. Mean costs of diagnostic measures were 402 €/alloHCT; however, only 22 % of the CT scans, 4 % of β-D and 3 % of galactomannan testing were positive. We detected one proven, 17 probable and 14 possible fungal infections. Due to the German diagnosis-related group system with additional compensation, all our AP/AT strategies were adequately reimbursed. While clinical symptoms and CT scans are the most commonly used, inexpensive decision-making tools for starting AT, the expensive laboratory diagnostic procedures are ineffective; we have therefore discontinued regular GAL/β-D testing and changed our AP in patients at risk. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
20. The combined use of unilateral pedicle screw and contralateral facet joint screw fixation in transforaminal lumbar interbody fusion.
- Author
-
Cao, Yuanwu, Chen, Zixian, Jiang, Chun, Wan, Shengcheng, Jiang, Xiaoxing, and Feng, Zhenzhou
- Subjects
- *
SPINAL fusion , *BONE screws , *ZYGAPOPHYSEAL joint , *LUMBAR vertebrae diseases , *DEGENERATION (Pathology) , *TREATMENT effectiveness , *THERAPEUTICS , *LUMBAR vertebrae surgery , *COMPARATIVE studies , *COMPUTED tomography , *LUMBAR vertebrae , *RESEARCH methodology , *MEDICAL cooperation , *POSTOPERATIVE period , *QUESTIONNAIRES , *RESEARCH , *SOFT tissue injuries , *THREE-dimensional imaging , *COST analysis , *EVALUATION research , *RANDOMIZED controlled trials , *SURGERY - Abstract
Purpose: This paper is to evaluate the efficacy and safety of transforaminal lumbar interbody fusion (TLIF) using unilateral pedicle screws along with contralateral translaminar facet joint screw (UPS+TFS) fixation in comparison with the method using bilateral pedicle screws fixation (BPS) in degenerative lumbar diseases.Methods: Forty patients with single-level lumbar diseases were divided into two groups randomly. One group was treated by TLIF with BPS fixation while the other group was treated by the new technique with UPS+TFS fixation. The preoperative and postoperative ODI, JOA, VAPS scores, mean operation time, mean operation blood loss, fusion rate and complications were collected for comparison under two surgical methods. In terms of complications, only two cases of superficial infection in the BPS group and one case of urinary tract infection in the other group was found.Results: The mean operation time and blood loss was significantly less in UPS+TFS group than in BPS group. The preoperation and postoperative ODI, JOA and VAPS at the intervals of 6 weeks, 3, 6 months and 1 year between the BPS and UPS+TFS group showed no significant disparities. Only one patient in UPS+TFS group was not fused with pseudoarthrosis formation.Conclusions: The clinical efficacy and safety of TLIF with UPS+TFS fixation were comparable to BPS fixation; however, the soft tissue injury and the corresponding operation cost were reduced with unilateral pedicle screw plus translaminar facet screw fixation. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
21. The role of biosimilar granulocyte colony stimulating factor (GCSF) Zarzio for progenitor cell mobilization and the treatment of therapy-induced neutropenia in adult hematopoietic stem cell transplantation.
- Author
-
Severson, Cherie C.
- Subjects
GRANULOCYTE-colony stimulating factor ,HEMATOPOIETIC stem cell transplantation ,NEUTROPENIA ,COST analysis ,TREATMENT effectiveness ,THERAPEUTICS - Abstract
Originator GCSF (Neupogen) has been used to mobilize progenitor stem cells and treat therapy-induced neutropenia in Canadian stem cell transplant settings for years. Although its benefit is not in question, viable alternatives are available. Biosimilar GCSF (Zarzio) is widely in use in Europe since 2009 and was recently approved in the U.S.for the same five indications as Neupogen. Zarzio is reported as safe, equally efficacious, more accessible and cost effective without negatively impacting patient outcomes. This paper summarizes the supporting evidence. [ABSTRACT FROM AUTHOR]
- Published
- 2015
22. Cost-Utility Analysis of Mycophenolate Mofetil versus Azathioprine Based Regimens for Maintenance Therapy of Proliferative Lupus Nephritis.
- Author
-
Nee, Robert, Rivera, Ian, Little, Dustin J., Yuan, Christina M., and Abbott, Kevin C.
- Subjects
- *
COST effectiveness , *QUALITY of life , *LUPUS nephritis , *COST analysis , *TREATMENT effectiveness , *QUALITY-adjusted life years , *MYCOPHENOLIC acid , *AZATHIOPRINE , *DRUG administration , *DRUG dosage , *THERAPEUTICS - Abstract
Background/Aims. We aimed to examine the cost-effectiveness of mycophenolate mofetil (MMF) and azathioprine (AZA) as maintenance therapy for patients with Class III and Class IV lupus nephritis (LN), from a United States (US) perspective. Methods. Using a Markov model, we conducted a cost-utility analysis from a societal perspective over a lifetime horizon. The modeled population comprised patients with proliferative LN who received maintenance therapy with MMF (2 gm/day) versus AZA (150 mg/day) for 3 years. Risk estimates of clinical events were based on a Cochrane meta-analysis while costs and utilities were retrieved from other published sources. Outcome measures included costs, quality-adjusted life-years (QALY), incremental cost-effectiveness ratios (ICER), and net monetary benefit. Results. The base-case model showed that, compared with AZA strategy, the ICER for MMF was $2,630,592/QALY at 3 years. Over the patients’ lifetime, however, the ICER of MMF compared to AZA was $6,454/QALY. Overall, the ICER results from various sensitivity and subgroup analyses did not alter the conclusions of the model simulation. Conclusions. In the short term, an AZA-based regimen confers greater value than MMF for the maintenance therapy of proliferative LN. From a lifelong perspective, however, MMF is cost-effective compared to AZA. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
23. Surgical site infection in elderly patients with hip fractures, silver-coated versus regular dressings: a randomised prospective trial.
- Author
-
Kadar, A., Eisenberg, G., and Yahav, E.
- Subjects
BACTERIA classification ,SILVER compounds ,SURGICAL site infection prevention ,ANTI-infective agents ,FISHER exact test ,BONE fractures ,HIP joint injuries ,HOST-bacteria relationships ,LONGITUDINAL method ,SURGICAL dressings ,T-test (Statistics) ,COST analysis ,RANDOMIZED controlled trials ,TREATMENT effectiveness ,DATA analysis software ,DESCRIPTIVE statistics ,ANTIBIOTIC prophylaxis ,OLD age ,THERAPEUTICS - Abstract
Objective: Surgical site infection (SSI) after hip fracture surgery is a well-known complication with serious consequences for both the patient and the medical system. Silver ion treatment is considered an effective antibacterial agent, however, the use of silver dressing (SD) in the primary prevention of SSIs is controversial. The aims of this study were to compare SD with regular dressing (RD) in the prevention of SSI in elderly patients undergoing surgery for hip fractures, and to compare costs. Method: A matched group of 55 patients with hip fractures undergoing surgery with dynamic hip screw, cephalomedullary nail or hemiarthroplasty were randomised to either SD or RD groups. The dressings were applied in the operating theatre, and the patients were followed for one week for clinical signs of infection (discharge, erythema and fever). The RDs were replaced daily. The SDs were not removed for 5-7 days and kept moist. Skin swabs were taken from the wound surface on postoperative day 5-7 for bacterial skin colonisation. Results: The SD (n=31) and RD (n=24) groups were similar in age, sex and comorbidities. Infection signs were seen in two (2/31, 6.4%) of the SD patients compared with 2 (2/24, 8.3%) RD patients (p=1.0). Skin colonisation by bacteria at postoperative day 5-7 was tested in 27 patients: it was higher in the SD group (positive skin swab, 12/19, 63.2%) compared to the RD group (4/8, 50%, p=0.67). The use of SD added ~US$5 (UK ~£3.19) per patient. Conclusion: The use of SD was associated with higher costs than RD, but not superior in preventing SSIs in elderly patients undergoing hemiarthroplasty or fixation of hip fractures. SD was also not effective in reducing bacterial skin colonisation following hip fracture and surgery. Declaration of interest: The authors have no conflict of interest to declare. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
24. Evaluating the Cost of Bringing People with Type 2 Diabetes Mellitus to Multiple Targets of Treatment in Canada.
- Author
-
Skovgaard, Rasmus, Jon Ploug, Uffe, Hunt, Barnaby, and Valentine, William J.
- Subjects
- *
INSULIN derivatives , *PIOGLITAZONE , *EXENATIDE , *SITAGLIPTIN , *GLUCAGON-like peptide-1 agonists , *COST effectiveness , *GLYCOSYLATED hemoglobin , *HYPOGLYCEMIC agents , *MEDICAL care costs , *TYPE 2 diabetes , *WEIGHT gain , *COST analysis , *TREATMENT effectiveness , *GLYCEMIC control , *ECONOMICS , *THERAPEUTICS - Abstract
Purpose Evidence suggests that clinical outcomes for people with type 2 diabetes mellitus can be improved through multifactorial treatment. The key challenges in the successful treatment of type 2 diabetes include maintaining tight glycemic control, minimizing the risk of hypoglycemia, controlling cardiovascular risk factors, and reducing or controlling weight. The aim of the present analysis was to evaluate the cost per patient achieving a composite clinical end point (glycosylated hemoglobin <7%, with no weight gain and no hypoglycemic events) in patients with type 2 diabetes in Quebec, Quebec, Canada, receiving liraglutide 1.2 mg, liraglutide 1.8 mg, thiazolidinedione, sulfonylurea, insulin glargine, sitagliptin, or exenatide. Methods The proportion of patients achieving control was taken from a meta-analysis that was based on the Phase III trial program of liraglutide. Treatment costs, estimated from a health care payer perspective, were calculated on the basis of the trials included in the meta-analysis and captured the study drug, needles, self-monitoring of blood glucose (SMBG) test strips, SMBG lancets, and other antidiabetes medications received. Cost-effectiveness in terms of cost per patient achieving the composite end point (cost of control) was evaluated with an economic model developed in Microsoft Excel. No discounting was applied to cost or clinical outcomes because these were not projected beyond a 1-year time horizon. Sensitivity analyses were performed. Findings Liraglutide 1.8 mg was associated with the lowest number needed to treat, with 3 patients needing to be treated to bring 1 patient to the composite end point. Pioglitazone was associated with the highest number needed to treat, with 17 patients requiring treatment to bring 1 patient to the composite end point. Evaluation of only annual pharmacy costs indicated that liraglutide 1.8 mg was the most costly treatment at Can$2780 per patient per year. Pioglitazone and glimepiride were associated with the lowest direct annual costs. Combining the clinical efficacy data with the annual cost of medications produced cost of control values of Can$6070 (liraglutide 1.2 mg), Can$6949 (liraglutide 1.8 mg), Can$7237 (glimepiride), Can$7704 (exenatide), Can$8297 (insulin glargine), Can$8741 (pioglitazone), and Can$9270 (sitagliptin) per patient achieving the composite end point. Implications Liraglutide 1.2 mg and 1.8 mg were associated with the lowest cost of control values, driven by the high proportion of patients achieving the composite end point, which offset the higher medication costs. A relatively low cost of control value was achieved for glimepiride, driven by low acquisition costs, despite relatively few patients achieving the composite end point. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
25. Management of periodontal disease in patients using calcium channel blockers - gingival overgrowth, prescribed medications, treatment responses and added treatment costs.
- Author
-
Fardal, Øystein and Lygre, Henning
- Subjects
- *
ACADEMIC medical centers , *CALCIUM antagonists , *PERIODONTITIS , *COST analysis , *TREATMENT effectiveness , *DESCRIPTIVE statistics , *MANN Whitney U Test , *PHARMACODYNAMICS , *THERAPEUTICS - Abstract
Objectives Gingival overgrowth ( GO) is an adverse drug reaction in patients using calcium channel blockers ( CCBs). Little is known about the effects of CCBs on the management of periodontal diseases. The aim of this study was to assess how the use of CCBs affects the long-term supportive treatment and outcomes in patients undergoing periodontal therapy. Methods All patients using CCBs during the initial treatment and/or the supportive periodontal therapy ( SPT) were selected from a periodontal practice. Patients were scored using a Gingival Overgrowth Index ( GOI). The effects of CCB types and dosages were assessed in terms of the frequency and the severity of GO, treatment responses, substitutions and extra treatment costs. Mean values, Standard Deviation ( SD) and range were calculated. The Mann-Whitney test was used to assess statistically significant differences ( p < 0.05) for GO between patients with good and poor oral hygiene, differences between before and after terminating or replacing the CCBs, possible differences between drug dosages (Dihydropyridine 5 mg and 10 mg) and differences between three drug combinations ( CCB and inhibitors of the renin-angiotensin system ( IRAS), CCB and non- IRAS, CCB and statins). Results One hundred and twenty-four patients (58 females, 66 males, 4.6% of the patient population) were using CCBs. 103 patients were assessed. Average age was 66.53 years ( SD. 9.89, range 42-88) and the observation time was 11.30 years ( SD 8.06, range 1-27). Eighty-nine patients had GO, 75 of these required treatment for GO. Terminating or replacing with alternatives to CCBs resulted in significant decreases in GO ( p = 0.00016, p = 0.00068) respectively. No differences were found between good and poor oral hygiene ( p = 0.074), drug dosages or the various drug combinations. Surgical treatment was more effective than non-surgical treatment in controlling the GO. Long-term tooth loss was 0.11 teeth per patient per year. Forty-two patients needed re-treatments for GO, resulting in an extra life cost per patient of €13471 (discounted €4177). Conclusion The majority of patients (86.4%) using CCBs experienced GO. 47.2% of these experienced recurrence(s) of GO during the SPT and needed re-treatments with resulting added costs. The long-term tooth loss was considerably higher for patients using CCBs than for other patients groups from the same practice setting. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
26. Clinical and economic outcomes of adjunctive therapy with pregabalin or usual care in generalized anxiety disorder patients with partial response to selective serotonin reuptake inhibitors.
- Author
-
Álvarez, Enrique, Olivares, José M., Carrasco, José L., López-Gómez, Vanessa, and Rejas, Javier
- Subjects
- *
PREGABALIN , *ANALYSIS of covariance , *CHI-squared test , *CONFIDENCE intervals , *COST effectiveness , *FISHER exact test , *LONGITUDINAL method , *RESEARCH funding , *SEROTONIN uptake inhibitors , *STATISTICS , *DATA analysis , *TREATMENT effectiveness , *DATA analysis software , *GENERALIZED anxiety disorder , *DESCRIPTIVE statistics , *MANN Whitney U Test , *THERAPEUTICS - Abstract
Background This study is done to compare the effect of adjunctive therapy with pregabalin versus usual care (UC) on health-care costs and clinical and patients consequences in generalized anxiety disorder (GAD) subjects with partial response (PR) to a previous selective serotonin reuptake inhibitor (SSRI) course in medical practice in Spain. Methods Post hoc analysis of patients with PR to SSRI monotherapy enrolled in a prospective 6-month naturalistic study was done. PR was defined as a Clinical Global Impression (CGI) scale score ≥3 and insufficient response with persistence of anxiety symptoms ≥16 in the Hamilton Anxiety Rating Scale (HAM-A). Two groups were analyzed: 1) adjunctive therapy (AT) with pregabalin (150–600 mg/day) to existing therapy and 2) UC (switching to a different SSRI or adding another anxiolytic different than pregabalin). Costs included GAD-related health-care resources utilization. Consequences were a combination of psychiatrist-based measurements [HAM-A, CGI, and Montgomery-Asberg Depression Rating Scale (MADRS)] and patientreported outcomes [Medical Outcomes Study Sleep (MOS-sleep) scale, disability (World Health Organization Disability Assessment Schedule II (WHO-DAS II) and quality-of-life (Euro Qol-5D (EQ-5D)]. Changes in both health-care costs and scale scores were compared separately at end-of-trial visit by a general linear model with covariates. Results Four hundred eighty-six newly prescribed pregabalin and 239 UC GAD patients [mean (SD) HAM-A 26.7 (6.9) and CGI 4.1 (0.5)] were analyzed. Adding pregabalin was associated with significantly higher mean (95% CI) score reductions vs. UC in HAM-A [–14.9 (–15.6; –14.2) vs. –11.2 (–12.2; –10.2), p < 0.001] and MADRS [–11.6 (–12.2; –10.9) vs. –7.8 (–8.7; –6.8), p < 0.001]. Changes in all patient-reported outcomes favored significantly patients receiving pregabalin, including quality-of-life gain; 26.4 (24.7; 28.1) vs. 19.4 (17.1; 21.6) in the EQ-VAS, p < 0.001. Health-care costs were significantly reduced in both cohorts yielding similar 6-month costs; €1,565 (1,426; 1,703) pregabalin and €1,406 (1,200; 1,611) UC, p = 0.777. The effect of sex on costs and consequences were negligible. Conclusion In medical practice, GAD patients with PR to SSRI experienced greater consequence improvements with adjunctive therapy with pregabalin versus UC, without increasing healthcare cost. The effect of pregabalin was independent of patient gender. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
27. A real-life clinical evaluation of a next-generation antimicrobial dressing on acute and chronic wounds.
- Author
-
Walker, M., Metcalf, D., Parsons, D., and Bowler, P.
- Subjects
ULCER treatment ,LEG ulcers ,WOUND care ,CHRONIC wounds & injuries ,ANTI-infective agents ,BIOFILMS ,MEDICAL cooperation ,RESEARCH ,SURGICAL dressings ,WOUND healing ,WOUNDS & injuries ,TRAUMATOLOGY diagnosis ,COST analysis ,VISUAL analog scale ,TREATMENT effectiveness ,DESCRIPTIVE statistics ,ECONOMICS ,THERAPEUTICS - Abstract
Objective: To assess the effectiveness of a new, next-generation antimicrobial dressing (AQUACEL Ag+ dressing) in facilitating healing in a variety of hard-to-heal wounds that may have been compromised by infection and/or biofilm. Method: This was an international, multi-centred, real-life, non-randomised evaluation involving patients with a wide variety of slow-, non-healing or deteriorating chronic and acute wounds. There were no strict inclusion or exclusion criteria and the clinicians were asked to use their discretion in the selection of patients. The clinicians continued to use their standard protocol of care but replaced their existing primary wound-contact dressing with the next-generation antimicrobial dressing (NGAD) for up to 4 weeks. Clinicians could extend the treatment period if this was deemed clinically appropriate. Baseline assessments included wound bed characteristics, exudate level, indicators of wound biofilm, and signs and symptoms of infection. At the final assessment, the investigators reported the wound size, wound bed characteristics, and exudate level. Results: A total of 121 patients were recruited into the original evaluation, of which eight were excluded for incomplete data sets. Most wounds (73; 64%) were either venous leg ulcers (59; 52%) or diabetic foot ulcers (14; 12%). At baseline, the wounds of (26; 23%) patients were slowly improving, 65 were stagnant (58%) and 22 (19%) were deteriorating. Just under three-quarters (74%) of the wounds had suspected biofilm (criteria including failure of a wound to heal, lack of response to topical and systemic antimicrobial agents, or the presence of slimy substances on the wound surface). Following the evaluations, the average wound closure achieved for all wounds was 72.6%, 19 (17%) wounds healed, 47 (42%) achieved at least 90% wound closure, and 71 (63%) achieved at least 75% closure. The average treatment period was 4.1 weeks; 35 wounds were treated with the dressing for more than 4 weeks. Cost analysis indicated that potential antimicrobial dressing cost reductions of approximately 30% were realised using the NGAD. Conclusion: This real-life, non-randomised evaluation provides encouraging evidence that the NGAD may have a role to play in facilitating wound progression towards healing by helping to eliminate the biofilm barrier. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
28. Liraglutide: A Review of Its Use in Adult Patients with Type 2 Diabetes Mellitus.
- Author
-
Scott, Lesley
- Subjects
- *
MEDICAL information storage & retrieval systems , *MEDLINE , *META-analysis , *TYPE 2 diabetes , *SAFETY , *SYSTEMATIC reviews , *COST analysis , *TREATMENT effectiveness , *DISEASE prevalence , *GLUCAGON-like peptide-1 agonists , *PHARMACODYNAMICS , *THERAPEUTICS - Abstract
Subcutaneous liraglutide (Victoza), a glucagon-like peptide 1 receptor agonist, is approved for the treatment of adult patients with type 2 diabetes mellitus. Once-daily liraglutide, as monotherapy or add-on therapy to other antidiabetic agents (including basal insulin), was an effective and generally well tolerated treatment in adult patients with type 2 diabetes in several well-designed phase III trials and in the real world clinical practice setting. In addition to improving glycaemic control, liraglutide had beneficial effects on bodyweight, systolic blood pressure and surrogate measures of β-cell function in clinical trials, with these benefits maintained during long-term treatment (≤2 years). Liraglutide has a convenient once-daily administration regimen, a low potential for drug-drug interactions and low propensity to cause hypoglycaemia. Thus, liraglutide continues to be a useful option for the management of type 2 diabetes. This article reviews the therapeutic use of liraglutide in adult patients with type 2 diabetes and summarizes its pharmacological properties. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
29. Economic evaluation of treatment for acute lymphoblastic leukaemia in childhood.
- Author
-
Rae, C., Furlong, W., Jankovic, M., Moghrabi, Albert, Naqvi, A., Sala, A., Samson, Y., DePauw, S., Feeny, D., and Barr, R.
- Subjects
- *
ANTINEOPLASTIC agents , *ACADEMIC medical centers , *COMBINATION drug therapy , *LYMPHOBLASTIC leukemia , *MEDICAL cooperation , *HEALTH outcome assessment , *QUALITY of life , *RESEARCH , *RESEARCH funding , *COST analysis , *TREATMENT effectiveness , *DATA analysis software , *THERAPEUTICS , *CHILDREN - Abstract
Berlin- Frankfurt- Munster ( BFM) and Dana- Farber Cancer Institute ( DFCI) consortia's treatment strategies for acute lymphoblastic leukaemia ( ALL) in children are widely used. We compared the health effects and monetary costs of hospital treatments for these two strategies. Parents of children treated at seven centres in Canada, Italy and the USA completed health-related quality of life ( HRQL) assessments during four active treatment phases and at 2 years after treatment. Mean HRQL scores were used to calculate quality-adjusted life years ( QALYs) for a period of 5 years following diagnosis. Total costs of treatment were determined from variables in administrative databases in a universally accessible and publicly funded healthcare system. Valid HRQL assessments ( n = 1200) were collected for 307 BFM and 317 DFCI patients, with costs measured for 66 BFM and 28 DFCI patients. QALYs per patient were <1.0% greater for BFM than DFCI. Median HRQL scores revealed no difference in QALYs. The difference in mean total costs for BFM ( US$88 480) and DFCI ( US$93 026) was not significant ( P = 0.600). This study provides no evidence of superiority for one treatment strategy over the other. Current BFM or DFCI strategies should represent conventional management for the next economic evaluation of treatments for ALL in childhood. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
30. First-line trastuzumab plus taxane-based chemotherapy for metastatic breast cancer: Cost-minimization analysis.
- Author
-
Nerich, Virginie, Chelly, Jennifer, Montcuquet, Philippe, Chaigneau, Loïc, Villanueva, Cristian, Fiteni, Frédéric, Meneveau, Nathalie, Perrin, Sophie, Voidey, Aline, Monnot, Tess, Pivot, Xavier, and Limat, Samuel
- Subjects
- *
HYDROCARBONS , *TRASTUZUMAB , *BREAST tumors , *CANCER chemotherapy , *CHI-squared test , *COST effectiveness , *FISHER exact test , *LONGITUDINAL method , *MEDICAL care costs , *METASTASIS , *NONPARAMETRIC statistics , *HEALTH outcome assessment , *SURVIVAL analysis (Biometry) , *TREATMENT effectiveness , *RETROSPECTIVE studies , *DATA analysis software , *DESCRIPTIVE statistics , *MANN Whitney U Test , *THERAPEUTICS - Abstract
Aim: To carry out a cost-minimization analysis including a comparison of the costs arising from first-line treatment by trastuzumab plus docetaxel versus trastuzumab plus paclitaxel in patients with metastatic breast cancer. Methods: All consecutive patients with human epidermal growth receptor 2-postive metastatic breast cancer who were treated at Besanc¸on University Hospital and Saint Vincent private hospital between 2001 and 2010 by first-line therapy containing trastuzumab plus taxane were retrospectively studied. Economic analysis took into account costs related to drugs, hospitalization, and healthcare travel. Results: Progression-free survival difference between the two treatments was not significant (p¼0.65). First-line treatment by trastuzumab plus taxane was estimated at approximately E68,000 (p¼0.74). The drug costs represented around 70–75% of the total cost, mainly related to the use of trastuzumab. Conclusion: Our economic analysis shows that although the costs of the two trastuzumab plus taxane regimens are similar, they may contribute to the on-going debate about the availability and use of innovative chemotherapy drugs, in particular in human epidermal growth factor receptor 2-positive metastatic breast cancer with new therapies such as trastuzumab-DM1 and pertuzumab. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
31. Acute and Chronic Tocolysis.
- Author
-
BOLDEN, JANELLE R.
- Subjects
- *
PREMATURE labor prevention , *PREMATURE infants , *EPIDEMIOLOGY , *HEALTH outcome assessment , *PREGNANCY , *COST analysis , *TREATMENT effectiveness , *PATIENT selection , *PHARMACODYNAMICS , *TOCOLYTIC agents , *THERAPEUTICS , *PREVENTION - Abstract
Preterm birth occurs in 12% of all births in the United States. Preterm labor precedes approximately half of these births. Tocolysis is used in the short term to prolong pregnancy long enough to administer corticosteroids and/or facilitate transfer to a tertiary care center. A number of agents have been used for this therapy, which will be discussed in the following chapter. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
32. Sevelamer Carbonate: A Review in Hyperphosphataemia in Adults with Chronic Kidney Disease.
- Author
-
Perry, Caroline and Plosker, Greg
- Subjects
- *
MEDICAL information storage & retrieval systems , *ION exchange resins , *MEDLINE , *META-analysis , *METABOLIC disorders , *ORAL drug administration , *HEALTH outcome assessment , *PHOSPHORUS in the body , *SAFETY , *SYSTEMATIC reviews , *COST analysis , *TREATMENT effectiveness , *THERAPEUTICS ,CHRONIC kidney failure complications - Abstract
Sevelamer carbonate (Renvela), a buffered form of sevelamer hydrochloride (Renagel), is an orally administered non-absorbed phosphate-binding anion exchange resin used in the treatment of hyperphosphataemia in chronic kidney disease (CKD). In the EU, sevelamer carbonate is approved in adult CKD patients who require dialysis and in those who do not require dialysis with serum phosphate levels ≥1.78 mmol/L, whereas in the USA sevelamer carbonate is approved in adult CKD patients who require dialysis. Sevelamer carbonate and sevelamer hydrochloride achieved similar reductions in serum phosphate levels in randomized comparative trials in patients with CKD receiving haemodialysis; sevelamer carbonate also reduced serum phosphate levels in noncomparative studies in CKD patients not requiring dialysis. The most common adverse events with sevelamer carbonate are gastrointestinal in nature. Sevelamer has pleiotropic effects, such as improving the serum lipid profile and attenuating endothelial and cardiovascular risk factors in CKD. All formulations of sevelamer have markedly higher acquisition costs than calcium-based phosphate binders. Cost-effectiveness analyses focusing specifically on sevelamer carbonate have not been conducted, and those based on clinical trial data with sevelamer hydrochloride have provided both favourable and unfavourable results compared with calcium-based phosphate binders, reflecting heterogeneity between modelled analyses in terms of data sources, assumptions, comparators, geographical regions, type of costs included and other factors. Although well-designed studies evaluating the impact of phosphate binders on hard clinical endpoints appear to be warranted, sevelamer carbonate may be particularly useful for the treatment of patients at risk of metabolic acidosis (offering advantages over sevelamer hydrochloride in this regard) and for individuals requiring treatment with a phosphate binding agent that does not contain aluminium or calcium. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
33. Efficacy and safety of canakinumab therapy in paediatric patients with cryopyrin-associated periodic syndrome: a single-centre, real-world experience.
- Author
-
Russo, Ricardo A. G., Melo-Gomes, Sonia, Lachmann, Helen J., Wynne, Karen, Rajput, Kaukab, Eleftheriou, Despina, Edelsten, Clive, Hawkins, Philip N., and Brogan, Paul A.
- Subjects
- *
THERAPEUTIC use of monoclonal antibodies , *ACADEMIC medical centers , *DOSE-response relationship in biochemistry , *INTERLEUKINS , *LONGITUDINAL method , *MONOCLONAL antibodies , *HEALTH outcome assessment , *QUALITY of life , *QUESTIONNAIRES , *SAFETY , *STATISTICS , *COST analysis , *DATA analysis , *TREATMENT effectiveness , *DATA analysis software , *DESCRIPTIVE statistics , *CHEMICAL inhibitors , *CRYOPYRIN-associated periodic syndromes , *CHILDREN , *THERAPEUTICS - Abstract
Objective. The aim of this study was to determine the short- and long-term efficacy and safety of 8-weekly canakinumab therapy in children with cryopyrin-associated periodic syndromes (CAPS) in routine clinical practice.Methods. A single-centre observational study was performed. Patients were assessed every 8 weeks at a dedicated clinic. Standardized assessments were the 10-domains DAS for CAPS, acute phase reactants (APRs), physician’s global assessment of disease activity, Child Health Assessment Questionnaire (CHAQ) and Child Health Questionnaire Parent Form 28 (CHQPF-28). The primary endpoint was clinical improvement, defined as a reduction of DAS score 8 weeks after commencing therapy. Secondary endpoints included sustained clinical improvement in APRs, relapses, CHAQ score and CHQPF-28 score.Results. Ten children with CAPS [eight Muckle-Wells syndrome (MWS), two chronic infantile cutaneous neurological articular (CINCA); median age 6.3 years] received 8-weekly canakinumab treatments at 2–8.7 mg/kg for a median of 21 months (range 12–31 months). Nine of 10 patients improved after the first dose: baseline median DAS of 7.5/20 decreased to 3.5/20 at 8 weeks (P = 0.04). This clinical improvement was sustained at a median follow-up of 21 months (range 12–31 months). Children with CINCA required higher doses of canakinumab than those with MWS. CHAQ and CHQ scores indicated improvement in functioning and health-related quality of life (HRQoL). Treatment was well tolerated, with no injection site reactions and no serious infections.Conclusion. Canakinumab, although costly, is a safe and effective treatment for CAPS in children, leading to sustained improvement in disease activity, serological markers, functional ability and HRQoL. [ABSTRACT FROM PUBLISHER]
- Published
- 2014
- Full Text
- View/download PDF
34. Oxycodone/Naloxone Prolonged-Release: A Review of Its Use in the Management of Chronic Pain While Counteracting Opioid-Induced Constipation.
- Author
-
Burness, Celeste and Keating, Gillian
- Subjects
- *
CONSTIPATION , *CONTROLLED release drugs , *COMBINATION drug therapy , *DRUGS , *DRUG side effects , *MEDICAL information storage & retrieval systems , *MEDLINE , *META-analysis , *NALOXONE , *HEALTH outcome assessment , *PAIN , *PHARMACOKINETICS , *QUALITY of life , *SYSTEMATIC reviews , *OXYCODONE , *COST analysis , *VISUAL analog scale , *TREATMENT effectiveness , *PHARMACODYNAMICS , *THERAPEUTICS , *PREVENTION - Abstract
A combination of prolonged-release (PR) oxycodone with PR naloxone (Targin, Targiniq, Targinact) in one tablet with a fixed 2:1 ratio is available for the treatment of patients with severe pain, which can only be adequately managed with opioid analgesics. The aim of this formulation is to counteract opioid-induced constipation through the local antagonist effect of naloxone in the gut wall, while maintaining analgesia due to the low bioavailability of oral naloxone. Three large, 12-week, randomized, double-blind, phase III trials in patients with moderate to severe, chronic, non-malignant pain, plus a prospectively planned pooled analysis of two of these studies, demonstrated that oxycodone/naloxone PR improved bowel function, as measured by the bowel function index, compared with oxycodone PR. Additionally, oxycodone/naloxone PR relieved pain more effectively than placebo and no less effectively than oxycodone PR after 12 weeks. Phase II efficacy data in cancer patients are consistent with those observed in patients with non-malignant pain. Oxycodone/naloxone PR was generally well tolerated; the most frequently reported adverse events were of gastrointestinal origin, consistent with those known to occur with opioid therapy. Of note, numerically lower rates of constipation were observed in the oxycodone/naloxone PR group compared with the oxycodone PR group. A cost-utility analysis predicted that oxycodone/naloxone PR would be a cost-effective option compared with oxycodone PR in patients with non-malignant pain. Although more comparative data are needed, oxycodone/naloxone PR is an effective option for use in patients with severe chronic pain, particularly among those with opioid-induced constipation. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
35. Cost-effectiveness of cognitive--behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care economic evaluation of the CoBalT Trial.
- Author
-
Hollinghurst, Sandra, Carroll, Fran E., Abel, Anna, Campbell, John, Garland, Anne, Jerrom, Bill, Kessler, David, Kuyken, Willem, Morrison, Jill, Ridgway, Nicola, Thomas, Laura, Turner, Katrina, Williams, Chris, Peters, Tim J., Lewis, Glyn, and Wiles, Nicola
- Subjects
COGNITIVE therapy ,COST effectiveness ,COST analysis ,DRUG therapy ,MENTAL depression ,THERAPEUTICS ,PRIMARY care ,ANTIDEPRESSANTS ,ALGORITHMS ,CONFIDENCE intervals ,EPIDEMIOLOGY ,HEALTH surveys ,INTERVIEWING ,LONGITUDINAL method ,HEALTH outcome assessment ,PRIMARY health care ,QUESTIONNAIRES ,REGRESSION analysis ,RESEARCH funding ,DATA analysis ,RANDOMIZED controlled trials ,TREATMENT effectiveness ,PRE-tests & post-tests ,REPEATED measures design ,DATA analysis software ,EVALUATION - Abstract
Background Depression is expensive to treat, but providing ineffective treatment is more expensive. Such is the case for many patients who do not respond to antidepressant medication. Aims To assess the cost-effectiveness of cognitive-behavioural therapy (CBT) plus usual care for primary care patients with treatment-resistant depression compared with usual care alone. Method Economic evaluation at 12 months alongside a randomised controlled trial. Cost-effectiveness assessed using a cost-consequences framework comparing cost to the health and social care provider, patients and society, with a range of outcomes. Cost-utility analysis comparing health and social care costs with quality-adjusted life-years (QALYS). Results The mean cost of CBT per participant was £910. The difference in QALY gain between the groups was 0.057, equivalent to 21 days a year of good health. The incremental cost-effectiveness ratio was £14911 (representing a 74% probability of the intervention being cost-effective at the National Institute of Health and Care Excellence threshold of £20000 per QALY). Loss of earnings and productivity costs were substantial but there was no evidence of a difference between intervention and control groups. Conclusions The addition of CBT to usual care is cost-effective in patients who have not responded to antidepressants. Primary care physicians should therefore be encouraged to refer such individuals for CBT. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
36. Individualising wound care research: The Woundcare for Epidermolysis Bullosa Project.
- Author
-
GROCOTT, PATRICIA, GRAHAM, TANYA, BLACKWELL, REBECCA, CURRIE, CONCHITA, PILLAY, ELIZABETH, CLAPHAM, JANE, GRAHAM-KING, PAULINE, HON, JENNIE, and SNELSON, KAREN
- Subjects
EPIDERMOLYSIS bullosa ,CLOTHING & dress ,AUTOMATIC data collection systems ,WOUND care ,CLINICAL medicine ,COMMERCIAL product evaluation ,CROSSOVER trials ,HUMAN comfort ,HEALTH outcome assessment ,PATIENT satisfaction ,STATISTICAL sampling ,SCALE analysis (Psychology) ,SURGICAL dressings ,WOUND healing ,QUALITATIVE research ,COST analysis ,PRODUCT design ,QUANTITATIVE research ,EVALUATION research ,KEY performance indicators (Management) ,TREATMENT effectiveness ,DESCRIPTIVE statistics ,ECONOMICS ,THERAPEUTICS ,EQUIPMENT & supplies - Abstract
The authors report The Woundcare for Epidermolysis Bullosa (WEB) Project, which undertook to design dressing retention garments to replace flat and tubular bandages traditionally used in wound care for EB. Participants with EB reported greater comfort, healing of persistent wounds, and enhanced self-esteem using the new garments, and an average annual saving of £10 943 per patient is estimated. [ABSTRACT FROM AUTHOR]
- Published
- 2013
37. Clinical Progression, Acute Urinary Retention, Prostate-Related Surgeries, and Costs in Patients with Benign Prostatic Hyperplasia Taking Early Versus Delayed Combination 5ɑ-Reductase Inhibitor Therapy and ɑ-Blocker Therapy: A Retrospective Analysis
- Author
-
Morlock, Robert, Goodwin, Bridgett, Rey, Gabriel Gomez, and Eaddy, Michael
- Subjects
- *
ADRENERGIC alpha blockers , *COMBINATION drug therapy , *CHI-squared test , *CONFIDENCE intervals , *DATABASES , *DIAGNOSIS , *EPIDEMIOLOGY , *FINASTERIDE , *MEDICAL information storage & retrieval systems , *MEDICAL errors , *MULTIVARIATE analysis , *HEALTH outcome assessment , *RESEARCH funding , *T-test (Statistics) , *U-statistics , *RETENTION of urine , *BENIGN prostatic hyperplasia , *LOGISTIC regression analysis , *COST analysis , *DATA analysis , *TREATMENT effectiveness , *RETROSPECTIVE studies , *EARLY medical intervention , *DESCRIPTIVE statistics , *THERAPEUTICS , *SYMPTOMS - Abstract
Background: Two previous retrospective database analyses compared early combination therapy with an ɑ-blocker (AB) and 5-ɑ reductase inhibitor (5-ARI) to delayed combination therapy and found that patients receiving the delayed combination therapy were more likely to have clinical progression, acute urinary retention (AUR), and surgery. Although these studies indicate the clinical benefits of early treatment, both studies failed to take into account important baseline clinical measures, such as prostate-specific antigen (PSA) values. Objective: This study was designed to compare clinical and cost differences in men with benign prostatic hyperplasia (BPH) who initiated early versus delayed combination therapy with a 5-ARI + an AB, factoring in baseline PSA values. Methods: This retrospective claims data analysis assessed data from >14 million US men with linked medical data, pharmacy data, laboratory results, and enrollment information from January 1, 2000, to December 31, 2009. Men aged 50 or older and treated for BPH with a 5-ARI + an AB were identified. Patients were required to be eligible for services at least 6 months before and 12 months after the index medication date. Patients were assigned to 1 of 2 treatment groups based on therapy (early or delayed) and 3 cohorts based on availability of PSA laboratory values (patients with a PSA value, patients with a PSA value >1.5 and <10, and all patients). Using a logistic model, the likelihood of clinical progression (defined as the occurrence of AUR or prostate surgery) during the 12 months after the date of first prescription fill was compared between BPH patients receiving early versus delayed combination therapy. BPH-related medical costs (excluding pharmacy costs) were assessed using generalized linear models. Results: Among the 13,551 patients identified for study inclusion, the highest risks for clinical progression, AUR, and prostate-related surgery were consistently demonstrated in patients with a PSA >1.5 and <10. Across all 3 cohorts, the delayed combination-treatment group was more likely to have clinical progression, AUR, and prostate-related surgeries versus the early combination- treatment group. The incremental difference in BPH-related costs between the delayed and early combination- treatment groups was $190 per patient overall; the greatest incremental difference ($397) was observed in patients with PSA >1.5 and <10. Conclusions: The results suggest that early initiation of combination therapy with 5-ARI + an AB, compared with delayed initiation, can reduce the risks for clinical progression, AUR, and prostate-related surgeries, as well as BPH-related medical costs, in patients with BPH. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
38. Managing dental caries with atraumatic restorative treatment in children: successful experience in three Latin American countries.
- Author
-
Estupiñán-Day, Saskia, Tellez, Marisol, Kaur, Sundeep, Milner, Trevor, and Solari, Alfredo
- Subjects
- *
CHILDREN'S dental care , *CAVITY prevention , *TREATMENT of dental caries , *DENTAL amalgams , *DIAGNOSIS of dental caries , *DENTAL hygienists , *DENTISTS , *EPIDEMIOLOGY , *DENTAL fillings , *LONGITUDINAL method , *REGRESSION analysis , *RESEARCH funding , *STATISTICAL sampling , *SCALE analysis (Psychology) , *STATISTICS , *SURVIVAL analysis (Biometry) , *COST analysis , *DATA analysis , *TREATMENT effectiveness , *INTER-observer reliability , *DATA analysis software , *DESCRIPTIVE statistics , *EVALUATION , *THERAPEUTICS - Abstract
Objective. To compare survival rates and cost differentials between the atraumatic restorative treatment (ART) technique and amalgams by type of dental personnel in Ecuador, Panama, and Uruguay. Methods. Children 7 to 9 years of age in rural and urban schools with at least one lesion with initial cavitated enamel caries or a dentinal lesion on a irst permanent molar were selected and randomized into the ART (intervention) or amalgam (control) group. Restoration failure was evaluated at 12 and 24 months. Cooperation and pain experienced during the proce- dures were measured. Cumulative and incident failure of restorations at 12 and 24 months was calculated for dentists who placed ART or amalgam restorations and auxiliaries who placed ART restorations at 12 months only. Results. The total sample comprised 1 629 children. Study groups were similar by coun- try, gender, and geographic location. Cumulative failure rate at 12 months varied by group: dentists' amalgam, 0.9% to 5.7%; dentists' ART, 2.0% to 10.5%; and auxiliaries' ART, 5.7% to 15.8%. At 24 months, higher cumulative failures were observed for the dentists' amalgam group compared with the dentists' ART group in Ecuador and Panama but not in Uruguay. Amalgam was least likely to have the best level of cooperation and an auxiliary using ART was associated with the least pain. The cost of using the ART approach for dental caries treatment, including retreatment, was roughly half that of using amalgam without retreatment. Conclusions. Having auxiliary personnel perform ART will lead to treatment survival that is expected to be lower than dentists using amalgam or ART. In spite of the greater risk of fail- ure, the rate is not unacceptable and potential cost savings are substantial. [ABSTRACT FROM AUTHOR]
- Published
- 2013
39. Economic Evaluation of Fulvestrant 500 mg Versus Generic Nonsteroidal Aromatase Inhibitors in Patients With Advanced Breast Cancer in the United Kingdom.
- Author
-
Das, Romita, Cope, Shannon, Ouwens, Mario, Turner, Pauline, and Howlett, Matthew
- Subjects
- *
AROMATASE inhibitors , *GENERIC drugs , *CONFIDENCE intervals , *COST effectiveness , *INFORMATION storage & retrieval systems , *MEDICAL databases , *MEDICAL information storage & retrieval systems , *MEDLINE , *META-analysis , *HEALTH outcome assessment , *RESEARCH funding , *SYSTEMATIC reviews , *COST analysis , *RANDOMIZED controlled trials , *TREATMENT effectiveness , *PATIENT selection , *THERAPEUTICS ,BREAST tumor prevention - Abstract
Objective: The goal of this study was to examine the cost-effectiveness of fulvestrant 500 mg for the treatment of first progression or recurrence of advanced breast cancer in postmenopausal patients compared with generic nonsteroidal aromatase inhibitors (anastrozole and letrozole) in the United Kingdom. Methods: A cost-utility model based on a time-instate approach was used. Clinical effectiveness estimates used in the model were derived from a network meta-analysis for overall survival and serious adverse events. Overall survival was extrapolated by using a Weibull distribution, and progression-free survival (PFS) estimates were derived from a simultaneous network meta-analysis and extrapolation of PFS curves by using the log-normal distribution. Data on resource use, costs, and utilities were based on various sources, including expert opinion and published data. To explore uncertainty, 1-way and probability sensitivity analyses were conducted. The study was conducted from the perspective of the UK National Health Service, and costs are reported in 2010/2011 British pounds. Results: The base case incremental cost-effectiveness ratio (ICER) for fulvestrant 500 mg versus letrozole was £34,528, with incremental costs of £14,383 and an incremental quality-adjusted life-year (QALY) of 0.417. Extended dominance occurred for anastrozole because the ICER for anastrozole versus letrozole was higher than the ICER for fulvestrant 500 mg versus anastrozole. Based on the probability sensitivity analyses, the probability that fulvestrant 500 mg was the most cost-effective treatment option was 3%, 20%, and 53% at a willingness-to-pay threshold of £20,000, £30,000, and £40,000 per QALY, respectively. According to the 1-way sensitivity analyses, the PFS estimates were the key drivers of the model results. Conclusions: Although fulvestrant 500 mg was found not to be a cost-effective option at a standard UK threshold of £20,000 to £30,000 per QALY, it may be relevant to apply a higher threshold due to the poor prognosis of patients with advanced breast cancer and the limited number of hormonal treatment options available for this stage of treatment. Certain subgroups may also benefit from fulvestrant as a treatment option; however, limited data are currently available to identify these subgroups. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
40. Oxaliplatin and Bolus-Modulated 5-Fluorouracil as a Second-Line Treatment for Advanced Pancreatic Cancer: Can Bolus Regimens Replace FOLFOX When Considered for Second Line?
- Author
-
Azmy, A., Abdelwahab, S., and Yassen, M.
- Subjects
- *
FLUOROURACIL , *OXALIPLATIN , *ACADEMIC medical centers , *ANTINEOPLASTIC agents , *DRUG side effects , *HEALTH outcome assessment , *PANCREATIC tumors , *COST analysis , *TREATMENT effectiveness , *DATA analysis software , *DESCRIPTIVE statistics , *KAPLAN-Meier estimator , *LOG-rank test , *THERAPEUTICS - Abstract
Objective. Comparing activity of 2 regimens combining oxaliplatin to bolus modulated fluorouracil as second line treatment in advanced pancreatic adenocarcinoma pretreated with gemcitabine-containing schedule. Methods. Forty eight patients with advanced pancreatic adenocarcinoma were randomly assigned to receive either FU 500 mg/m2 IV bolus weekly ×6 weeks plus leucovorin 500 mg/m2 IV weekly for 6 weeks during each 8-week cycle plus oxaliplatin 85 mg/m2 IV on weeks 1, 3, and 5 of each 8-week (FLOX) OR receive weekly intravenous infusions of oxaliplatin 40 mg/m2, 5-FU 500 mg/m2, and leucovorin 250 mg/m2 (3 weeks on, 1 week off). Results. Non progression (PR+SD) was found in 33.5% for first regimen and 29% for second regimen, and 37.5% had clinical benefit (FLOX regimen) compared to 50% in 3-weeks regimen. The median TTP was 3.9,4 months respectively. Median OS was 8, 9 months for both regimens. Only one case in 3-weeks arm suffered from grade IV diarrhea. Two cases > grade 2 neutropenia were observed; one in each treatment groups. Grade 3 anemia was recorded in 3 patients (2 in FLOX arm, one in 3-weeks arm). Conclusions. Both regimens showed encouraging efficacy, acceptable toxicity, and clinical benefit. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
41. Intrapleural Fibrinolytics in the Management of Empyema.
- Author
-
Fitzsimons, Emma and Thomson, Anne
- Subjects
- *
EMPYEMA , *FIBRINOLYSIS , *HEALTH outcome assessment , *COST analysis , *TREATMENT effectiveness , *CHILDREN , *THERAPEUTICS - Published
- 2012
- Full Text
- View/download PDF
42. Cost-Effectiveness Analysis of Autologous Chondrocyte Implantation: A Comparison of Periosteal Patch Versus Type I/III Collagen Membrane.
- Author
-
Samuelson, Eric M. and Brown, David E.
- Subjects
- *
CARTILAGE cell transplantation , *COLLAGEN , *AUTOGRAFTS , *COMPARATIVE studies , *COMPUTER simulation , *COST effectiveness , *DECISION trees , *MEDICAL care costs , *HEALTH outcome assessment , *QUALITY of life , *REOPERATION , *THERAPEUTIC complications , *COST analysis , *TREATMENT effectiveness , *DATA analysis software , *DESCRIPTIVE statistics , *THERAPEUTICS - Abstract
Background: Autologous chondrocyte implantation (ACI) involves the use of a periosteal patch (ACI-P) as a cover for transplanted chondrocytes. Theoretically, this periosteal patch provides mesenchymal stem cells and growth factors that encourage chondrocyte development/differentiation. However, there is a significant rate of graft hypertrophy with the use of periosteum compared with using a type I/III collagen patch (ACI-C). This type I/III collagen patch, although not approved by the United States Food and Drug Administration for ACI, has been used extensively in Europe and in an “off-label” nature in the United States as a cover during ACI.Purpose: To examine the cost effectiveness of ACI and determine whether ACI-C is more cost effective than ACI-P.Study Design: Economic and decision analysis; Level of evidence, 2.Methods: Outcome data and complication rates from patients undergoing ACI (ACI-P and ACI-C) were derived from the best evidence in the literature. Costs were determined by examining the typical patient charges undergoing ACI at a local orthopaedic hospital. The costs, results, and complication rates were used to develop a decision analysis model comparing ACI-P to ACI-C.Results: The cost of ACI-P was $66,752 and for ACI-C was $66,939.50 ($187.50 difference). The cost per quality-adjusted life year (QALY) for ACI-P was $9466 compared with $9243 for ACI-C. Sensitivity analysis was performed regarding the additional cost of the type I/III collagen patch ($780) in ACI-C as well as the rate of graft hypertrophy after ACI-P (25%). This analysis revealed that the cost of the type I/III collagen patch would have to reach $1721, or the rate of graft hypertrophy after ACI-P reduced to almost 11%, before ACI-P became more cost effective than ACI-C.Conclusion: This cost-effectiveness analysis reveals that, while both ACI-P and ACI-C are cost effective, ACI-C is slightly more cost effective than ACI-P. This is likely secondary to the significant rate of patch-related complications associated with ACI-P, which is significantly reduced with ACI-C. Although the model is very sensitive to differences in outcomes between ACI-P and ACI-C, there is no high-quality evidence to suggest that there is a significant difference between the two. Thus, ACI-P becomes more cost effective if the cost of the type I/III collagen membrane is significantly increased or if the rate of graft hypertrophy after ACI-P were to be markedly reduced. [ABSTRACT FROM PUBLISHER]
- Published
- 2012
- Full Text
- View/download PDF
43. Ticagrelor: Oral Reversible P2Y12 Receptor Antagonist for the Management of Acute Coronary Syndromes
- Author
-
Cheng, Judy W.M.
- Subjects
- *
THROMBOSIS prevention , *ACADEMIC medical centers , *CLINICAL trials , *CORONARY disease , *HEALTH outcome assessment , *SAFETY , *COST analysis , *TREATMENT effectiveness , *PHARMACODYNAMICS , *PLATELET aggregation inhibitors , *THERAPEUTICS - Abstract
Abstract: Background: The clinical benefits of dual antiplatelet treatment (aspirin + clopidogrel) in the management of acute coronary syndromes (ACS) are well established. However, clopidogrel is a prodrug that requires hepatic activation. Concerns regarding its delayed onset of action, variability in antiplatelet effects, and prolonged recovery of platelet function after discontinuation have prompted the development of P2Y12 receptor antagonists. Ticagrelor is the most recently developed P2Y12 receptor antagonist available in the United States. Ticagrelor is a nonthienopyridine antiplatelet agent and is the first reversible oral antagonist of the P2Y12 receptors. Objective: This article reviews the pharmacology, clinical efficacy, and tolerability of ticagrelor use in management of ACS. Methods: Peer-reviewed clinical trials, review articles, and relevant treatment guidelines published from 1966 to March 15, 2012, were identified from the MEDLINE and Current Content databases using the search terms ticagrelor, ACS, pharmacokinetics, pharmacodynamics, pharmacoeconomics, and cost-effectiveness. Citations from available articles were also reviewed for additional references. Results: Nine pharmacokinetics/pharmacodynamics studies in humans and 1 clinical study were identified. In addition, the findings from 6 subanalyses based on the clinical study were included. Compared with clopidogrel, ticagrelor was associated with a significantly reduced composite rate of death from cardiovascular causes, myocardial infarction, or stroke (ticagrelor, 9.8%; clopidogrel, 11.7%; hazard ratio [HR] = 0.84; 95% CI, 0.77–0.92; P < 0.001). The difference in the rates of major bleeding was not significant (ticagrelor, 11.6%; clopidogrel, 11.2%). Ticagrelor was associated with a higher rate of non–coronary artery bypass graft surgery related major bleeding (4.5% vs 3.8%; P = 0.03), including fatal intracranial bleeding (0.1% vs 0.01%; P = 0.02), and fewer cases of other types of fatal bleeding (0.1% vs 0.3%; P = 0.03). Other adverse events reported with ticagrelor use included dyspnea (13.8%), headache (6.5%), and bradyarrhythmia (5.8%). The effects of ticagrelor have not been compared to those of other antiplatelet agents, including prasugrel. Conclusions: Based on the findings from the present review, ticagrelor provides reversible inhibition of adenosine diphosphate–induced platelet aggregation, with a faster onset of action than clopidogrel, and is effective in the treatment of patients with ACS. More data are required to definitively position ticagrelor with respect to other antiplatelet agents, including prasugrel. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
44. Recombinant-activated factor VII in patients with uncontrolled bleeding: A retrospective observational analysis.
- Author
-
Abuhasna, Said D., Al Jundi, Amer H., and Tarifi, Hashem A
- Subjects
- *
BLOOD coagulation factors , *HEMORRHAGE , *MEDICAL records , *SCIENTIFIC observation , *HEALTH outcome assessment , *SAFETY , *COST analysis , *TREATMENT effectiveness , *RETROSPECTIVE studies , *DESCRIPTIVE statistics , *THERAPEUTICS - Abstract
Background: Factor VIIa (recombinant) has an off-label use to control life-threatening bleeding that is refractory to other measures and was shown to decrease transfusion requirements. Objective: The primary objective of this study was to assess the safety and effectiveness of factor VIIa (recombinant) on blood transfusion requirements and coagulation parameters when used in patients whose bleeding was uncorrected by other means. The pharmacoeconomic impact for any discrepancy from our protocol was evaluated. Secondary outcomes included 4-hour and 28-day mortality, as well as safety of this agent in terms of thromboembolic complications. Materials and Methods: We retrospectively evaluated patients who received recombinant-activated factor VII (rFVIIa) for uncontrolled bleeding from June 2008 to April 2011. The medical records of 33 patients were evaluated. Coagulation parameters and blood products were determined 24 hours before and 24 hours after administration of rFVIIa, and the results compared. Patients were also screened for any thromboembolic complications. Results: Administration of rFVIIa reduced blood transfusion requirements and improved coagulation parameters significantly (P<0.05). No thromboembolic complications were reported. Most of the dosing was consistent with those recommended in our institutional protocol, with discrepancies resulting in an average cost of $56 058. Moreover, pH was reported in only 67% of patients. All patients treated with rFVIIa survived up to 4 hours after receiving this agent, while the 28-day mortality was 24% (8/33). Conclusion: The use of rFVIIa appears to be safe and effective in promoting hemostasis, as evident from reducing transfusion requirements and improving the coagulation variables. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
45. Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome.
- Author
-
Knoebel, Randall W, Lo, Mimi, and Crank, Christopher W
- Subjects
- *
CANCER chemotherapy , *ACADEMIC medical centers , *ANALYSIS of variance , *BODY weight , *FISHER exact test , *LEUKEMIA , *LYMPHOMAS , *HEALTH outcome assessment , *LYMPHOPROLIFERATIVE disorders , *OXIDOREDUCTASES , *T-test (Statistics) , *URIC acid , *LOGISTIC regression analysis , *COST analysis , *TREATMENT effectiveness , *RETROSPECTIVE studies , *PREVENTION , *THERAPEUTICS - Abstract
Purpose: Rasburicase is a recombinant urate oxidase enzyme generally reserved for the treatment or prevention of hyperuricemia in patients that are at high risk of developing tumor lysis syndrome (TLS). The primary objective of this study is to evaluate and characterize the outcomes of patients receiving low dose rasburicase for treatment or prophylaxis of hyperuricemia secondary to TLS.Patients/Methods: A retrospective chart review between April 1, 2007 and September 31, 2008 was completed. All adult patients who received a dose of 0.05mg/kg with either a leukemia or lymphoma diagnosis in addition to at least two TLS risk factors: WBC ≥ 50 × 109/L, LDH 2 × ULN, uric acid ≥ 8 mg/dl, SCr ≥ 1.5 mg/dl were included. Forty-eight patients received rasburicase for prophylaxis (n = 18) or treatment (n = 30) of TLS.Results: Forty patients achieved and maintained a uric acid less than 8 mg/dL, 24 h after receipt of a single dose of rasburicase without the requirement for renal replacement therapy. A statistically significant decrease in UA was achieved in all patients when compared to baseline (p < 0.001). Cost analysis revealed a $ 1.96 million (96%) direct cost savings for the 48 patients in this study when compared to the cost of manufacturer’s dosing recommendation.Conclusions: Low dose rasburicase was efficacious and cost effective for both prophylaxis and treatment of TLS. Administration of a single dose of 0.05mg/kg of rasburicase was sufficient in correcting uric acid levels for most patients. [ABSTRACT FROM PUBLISHER]
- Published
- 2011
- Full Text
- View/download PDF
46. Long-term effectiveness of collaborative depression care in older primary care patients with and without PTSD symptoms.
- Author
-
Chan, Domin, Fan, Ming-Yu, and Unützer, Jürgen
- Subjects
- *
MENTAL depression , *THERAPEUTICS , *ANALYSIS of variance , *CHI-squared test , *COMPUTER software , *INTERVIEWING , *MEDICAL care costs , *HEALTH outcome assessment , *POST-traumatic stress disorder , *PRIMARY health care , *PSYCHOTHERAPY , *STATISTICAL sampling , *COMORBIDITY , *COST analysis , *DATA analysis , *RANDOMIZED controlled trials , *TREATMENT effectiveness , *SEVERITY of illness index , *OLD age - Abstract
Objective: Depressed patients with comorbid post-traumatic stress disorder (PTSD) are more functionally impaired and may take longer to respond to depression treatment than patients without PTSD. This study examined the long-term effects of PTSD on depression severity, treatment response, and health care costs among older adults. Methods: Patients were recruited from 18 primary care clinics in five states. A total of 1801 patients aged 60 years or older with major depression or dysthymia were randomized to Improving Mood Promoting Access to Collaborative Treatment (IMPACT) collaborative care or usual care. The study included 191 (10.6%) subjects who screened positive for PTSD. Depression severity, assessed by the Hopkins Depression Symptom Checklist, was used to estimate depression-free days (DFDs) over 24 months. Total health care costs included inpatient, outpatient, and pharmacy costs. Results: Depressed patients with PTSD had higher depression severity than patients without PTSD symptoms at baseline. Over 2 years, intervention patients with PTSD symptoms had relatively the same benefits from collaborative care (99 more DFDs than usual care patients) as patients without PTSD (108 more DFDs than usual care) ( p¼0.85). Total health care costs did not differ significantly for depressed patients with and without PTSD symptoms. Conclusion: Depressed older adults with PTSD symptoms were more depressed at baseline, but collaborative care (compared to usual care) produced similar improvements in depression severity in both groups. This reduction of depression symptoms was observed for up to 12 months after the intervention ended, suggesting that long-term improvements in depression are possible with collaborative care in patients with and without PTSD symptoms. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
47. Multipractitioner Upledger CranioSacral Therapy: Descriptive Outcome Study 2007-2008.
- Author
-
Harrison, Rachel E. and Page, John S.
- Subjects
- *
ANXIETY treatment , *THERAPEUTICS , *MENTAL depression , *PAIN management , *ALTERNATIVE medicine , *ANALYSIS of variance , *ATTITUDE (Psychology) , *DRUG therapy , *CRANIOSACRAL therapy , *MEDICAL care use , *MEDICAL care costs , *HEALTH outcome assessment , *PATIENTS , *RESEARCH funding , *COST analysis , *TREATMENT effectiveness , *RETROSPECTIVE studies - Abstract
Objectives: This study describes patients presenting for CranioSacral treatment, the conditions they present with, and the impact of treatment on both their symptoms and lives. Design: The records of 157 patients treated with Upledger CranioSacral Therapy (UCST) were reviewed. Seventy-three (73) patients had been treated by 10 different practitioners working independently and 84 patients were treated by a single practitioner working within the National Health Service. Results: Patients' ages ranged from neonates to 68 years. Seventy-four percent (74%) of patients reported a valuable improvement in their presenting problem. Sixty-seven percent (67%) also reported a valuable improvement in their general well-being and/or a second health problem. Outcome by diagnostic groups suggested that UCST is particularly effective for patients with headaches and migraine, neck and back pain, anxiety and depression, and unsettled babies. Seventy percent (70%) of patients on medication decreased or discontinued it, and patients' average general practitioner consultation rate fell by 60% in the 6 months following treatment. Conclusions: The study suggests that further research into UCST as a treatment modality would be valuable for the abovementioned problems in particular. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
48. An Observational, Prospective Survey Assessing the Control of Atrial Fibrillation in Asia Pacific: Rationale and Design of the RecordAF-AP Registry.
- Author
-
Amerena, John, Chen, Shih-Ann, Sriratanasathavorn, Charn, Cho, Jeong-Gwan, Dejia, Huang, Omar, Razali, Fat, Tse Hung, and King, Anthony
- Subjects
- *
ATRIAL fibrillation prevention , *CARDIAC glycosides , *ARRHYTHMIA , *CONFIDENCE intervals , *REPORTING of diseases , *LONGITUDINAL method , *SCIENTIFIC observation , *HEALTH outcome assessment , *RESEARCH funding , *SURVEYS , *LOGISTIC regression analysis , *COST analysis , *TREATMENT effectiveness , *THERAPEUTICS - Abstract
Background: The literature suggests that the prevalence of atrial fibrillation (AF) may be lower in Asian countries than in Western countries. Nevertheless, AF remains a significant public health problem in the region. The burden of AF, the experiences of previous trials and the lack of data on AF and its management in Asia Pacific highlight the need for a comprehensive prospective study of AF management. Methods: The REgistry on Cardiac rhythm disORDers assessing the control of Atrial Fibrillation Asia Pacific (RecordAF-AP) is a prospective, observational survey of the management of recently diagnosed AF patients with 1-year follow-up in 8 countries across Asia Pacific. Eligible patients presenting with AF, treated or not, will be included in the registry and data will be recorded prospectively during follow-up visits at 6 and 12 months. Results: RecordAF-AP will recruit more than 3000 patients. Study recruitment commenced in April 2009 and the final results anticipated at the end of 2011. Conclusions: RecordAF-AP will assess the real-life management of AF patients in Asia Pacific, including a comparison of clinical outcomes in rhythm versus rate control strategies, providing much needed insight into the costs, treatment choices and clinical outcomes of AF patients in this region. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
49. Evaluation and economic impact analysis of different treatment options for ankle distortions in occupational accidents.
- Author
-
Audenaert, Amaryllis, Prims, Jente, Reniers, Genserik L.L., Weyns, Dirk, Mahieu, Peter, and Audenaert, Emmanuel
- Subjects
- *
SICK leave , *SURGICAL casts , *ANKLE , *ORTHOPEDIC casts , *CHI-squared test , *COLD therapy , *WORK-related injuries , *MEDICAL care costs , *HEALTH outcome assessment , *REGRESSION analysis , *SPRAINS , *STATISTICAL hypothesis testing , *STATISTICS , *COST analysis , *DATA analysis , *TREATMENT effectiveness , *SEVERITY of illness index , *COMPRESSION therapy , *ECONOMICS , *THERAPEUTICS , *DIAGNOSIS - Abstract
Rationale, aims and objectives Appropriate use of diagnostic and treatment modalities are essential for rational use of resources. The aim of this study is to evaluate the use of diagnostic modalities and different treatment options and their economic impacts following an acute ankle distortion resulting from an occupational accident. We evaluated the type-of-treatment impact on the victims' course of recovery as well as its impact on the associated accident costs. Research was carried out in Belgium. Methods An ankle distortion victims' database consisting of 200 cases of (Belgian) occupational accidents during the period 2005–2007 was analysed. Results Patients who were prescribed immobilization or the use of adjuvant support or physical therapy (118 cases) were not employed during a period of 37 days on average, with a mean total cost of 3140.14 Euros caused by the ankle sprain. Patients without any adjuvant therapy (82 cases) were characterized by an unemployment rate of 15 days on average, and a total cost of 1077.86 Euros. Cast immobilization, although its application is not supported by evidence-based literature, was still applied in 36% of the population studied and resulted in the longest average absence of work of 42 days with an obvious significant increase in medical and total costs. Conclusions Our results show a high rate of inappropriate use of cast immobilizations for ankle distortions. From an economic point of view and for the same clinical endpoint (being full resumption of the occupational activities), simple conventional treatment, consisting of rest, ice, compression and elevation at diagnosis with allowance of early weight bearing in the further clinical course, leads to the quickest full resumption of activities in combination with the lowest medical costs, if compared with any other kind of treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
50. Cost analysis model of outpatient management of ovarian hyperstimulation syndrome with paracentesis: “Tap early and often” versus hospitalization
- Author
-
Csokmay, John M., Yauger, Belinda J., Henne, Melinda B., Armstrong, Alicia Y., Queenan, John T., and Segars, James H.
- Subjects
- *
OVARIAN hyperstimulation syndrome , *OVARIAN diseases , *COST analysis , *HOSPITAL care , *MATHEMATICAL models , *MEDICAL care costs , *PARACENTESIS , *PROBABILITY theory , *THERAPEUTICS , *OUTPATIENT medical care , *COMPARATIVE studies , *COST control , *COST effectiveness , *DECISION trees , *LENGTH of stay in hospitals , *HOSPITAL costs , *RESEARCH methodology , *MEDICAL cooperation , *RESEARCH , *TIME , *EVALUATION research , *TREATMENT effectiveness , *RETROSPECTIVE studies , *SEVERITY of illness index , *PATIENT selection , *STATISTICAL models , *ECONOMICS - Abstract
Objective: To compare the cost of two treatment regimens for moderate to severe ovarian hyperstimulation syndrome (OHSS): conservative inpatient versus outpatient management with paracentesis.Design: A decision-tree mathematical model comparing conservative inpatient versus outpatient management of moderate to severe OHSS was created. The common final pathway of either management was resolution of OHSS. Sensitivity analyses were performed over the range of variables.Main Outcome Measure(s): Total management cost of OHSS.Result(s): The cost of conservative therapy including first-tier complications was $10,099 (range $9,655-$15,044). The cost of outpatient management with paracentesis was $1954 (range $788-$12,041). This resulted in an estimated cost savings of $8145 with outpatient management with paracentesis. One-way sensitivity analyses were performed. Varying the probability of admission after outpatient treatment still indicated that outpatient treatment was the most cost-effective (probability = 1.0, cost = $6110). Varying the duration of hospitalization with primary inpatient treatment was equal to outpatient treatment costs only at a stay of 0.71 days or shorter.Conclusion(s): Our model suggests early outpatient paracentesis for moderate to severe OHSS is the most cost-effective management plan when compared with traditional conservative inpatient therapy. The cost savings for outpatient management persisted throughout a variety of outcome probabilities. [ABSTRACT FROM AUTHOR]- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.